Achari Ventures Holdings Corp. I (AVHI) S-4/A 30 Apr 24 Registration of securities issued in business combination transactions (amended) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2023
Document Information Line Items
Entity Registrant Name	Achari Ventures Holdings Corp. I
Document Type	S-4/A
Amendment Flag	true
Amendment Description	AMENDMENT NO. 3
Entity Central Index Key	0001844507
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	DE

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash	$ 48,395	$ 597,306
Prepaid expenses	48,106	180,197
Total current assets	96,501	777,503
OTHER ASSETS
Cash and marketable securities held in Trust Account	6,049,745	44,688,320
TOTAL ASSETS	6,146,246	45,465,823
CURRENT LIABILITIES
Accounts payable and accrued expenses	3,206,121	665,059
Income taxes payable	42,717	216,203
Franchise tax payable		291,137
Excise tax liability	391,544
Common Stock Redemption Payable		34,198,758
Total current liabilities	4,222,382	35,371,157
Derivative warrant liabilities	107,713	356,666
Deferred underwriting fee payable	3,500,000	3,500,000
Total liabilities	7,830,095	39,227,823
COMMITMENTS AND CONTINGENCIES (NOTE 6)
REDEEMABLE COMMON STOCK
Common stock subject to possible redemption: 550,941 and 1,019,465 shares at redemption value of $10.98 and $10.29 per share at December 31, 2023 and 2022, respectively	6,049,745	10,489,562
STOCKHOLDERS’ DEFICIT
Preferred stock
Common stock	250	250
Accumulated deficit	(7,733,844)	(4,251,812)
Total stockholders’ deficit	(7,733,594)	(4,251,562)
LIABILITIES, REDEEMABLE COMMON STOCK, AND STOCKHOLDERS’ DEFICIT	6,146,246	45,465,823
Vaso Corporation and Subsidaries
CURRENT ASSETS
Cash	11,342,000	11,821,000
Short-term investments	13,979,000	8,504,000
Accounts and other receivables, net of an allowance for credit losses and commission adjustments of $9,708 at December 31, 2023 and $6,947 at December 31, 2022	12,377,000	14,514,000
Inventories, net	1,470,000	1,473,000
Deferred commission expense	3,285,000	3,249,000
Prepaid expenses and other current assets	1,717,000	1,008,000
Total current assets	45,099,000	40,990,000
Property and equipment, net of accumulated depreciation of $10,358 at December 31, 2023 and $9,787 at December 31, 2022	1,174,000	1,340,000
Operating lease right of use assets	1,949,000	1,568,000
Goodwill	15,588,000	15,614,000
Intangibles, net	1,406,000	1,511,000
Other assets, net	4,902,000	4,726,000
Investment in EECP Global	683,000	889,000
Deferred tax assets, net	4,956,000	5,007,000
OTHER ASSETS
TOTAL ASSETS	75,757,000	71,645,000
CURRENT LIABILITIES
Accounts payable	2,670,000	2,270,000
Accrued commissions	2,411,000	3,518,000
Accrued expenses and other liabilities	7,365,000	8,891,000
Finance lease liabilities – current	72,000	122,000
Operating lease liabilities – current	928,000	745,000
Sales tax payable	699,000	809,000
Deferred revenue – current portion	15,883,000	15,139,000
Note payable-related party	9,000	9,000
Total current liabilities	30,040,000	31,506,000
COMMITMENTS AND CONTINGENCIES (NOTE 6)
LONG-TERM LIABILITIES
Notes payable, net of current portion	6,000	15,000
Finance lease liabilities, net of current portion	25,000	96,000
Operating lease liabilities, net of current portion	1,020,000	823,000
Deferred revenue, net of current portion	16,317,000	15,664,000
Other long-term liabilities	1,506,000	1,474,000
Total long-term liabilities	18,874,000	18,072,000
STOCKHOLDERS’ DEFICIT
Preferred stock
Common stock	186,000	185,000
Additional paid-in capital	63,993,000	63,952,000
Accumulated deficit	(35,032,000)	(39,837,000)
Accumulated other comprehensive loss	(304,000)	(233,000)
Treasury stock, at cost, 10,308,087 shares at December 31, 2023 and 2022	(2,000,000)	(2,000,000)
Total stockholders’ deficit	26,843,000	22,067,000
LIABILITIES, REDEEMABLE COMMON STOCK, AND STOCKHOLDERS’ DEFICIT	75,757,000	71,645,000
Related Party
CURRENT LIABILITIES
Note payable-related party	582,000
Related Party | Vaso Corporation and Subsidaries
CURRENT ASSETS
Receivables due from related parties	929,000	421,000
CURRENT LIABILITIES
Due to related party	$ 3,000	$ 3,000

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Temporary equity, shares outstanding	550,941	1,019,465
Temporary equity, redemption price per share (in Dollars per share)	$ 10.98	$ 10.29
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	2,500,000	2,500,000
Common stock, shares outstanding	2,500,000	2,500,000
Vaso Corporation and Subsidaries
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	185,627,383	185,435,965
Common stock, shares outstanding	175,319,296	175,127,878
Accounts and other receivables, net of an allowance for credit losses and commission adjustments (in Dollars)	$ 9,708	$ 6,947
Property and equipment, net of accumulated depreciation (in Dollars)	$ 10,358	$ 9,787
Treasury stock, at cost, shares	10,308,087	10,308,087

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
OPERATING EXPENSES
General and administrative	$ 3,098,140	$ 1,287,276
Franchise tax	81,600	282,342
Total operating expenses	3,179,740	1,569,618
OTHER INCOME
Interest and dividend income on cash and marketable securities held in Trust Account	429,125	1,411,854
Change in fair value of private warrants	248,953	1,997,334
Total other income	678,078	3,409,188
INCOME BEFORE INCOME TAX PROVISION	(2,501,662)	1,839,570
Income tax provision	$ (72,980)	$ (216,203)
Income per common share
Diluted net (loss) income per share, Common Stock (in Dollars per share)	$ (0.77)	$ 0.13
Weighted average common shares outstanding
NET (LOSS) INCOME	$ (2,574,642)	$ 1,623,367
Weighted average shares outstanding of Common Stock Basic (in Shares)	3,336,745	12,278,562
Basic net (loss) income per share, Common Stock (in Dollars per share)	$ (0.77)	$ 0.13
Vaso Corporation and Subsidaries
OPERATING EXPENSES
Selling, general and administrative	$ 45,643,000	$ 40,843,000
Research and development	755,000	605,000
Total operating expenses	46,398,000	41,448,000
Operating income	4,195,000	6,454,000
OTHER INCOME
Interest and financing costs	(50,000)	(44,000)
Interest and other income, net	764,000	143,000
Loss on disposal of fixed assets	(4,000)	(2,000)
Total other income	710,000	97,000
INCOME BEFORE INCOME TAX PROVISION	4,905,000	6,551,000
Income tax provision	(100,000)	4,743,000
Other comprehensive income
Foreign currency translation loss	(71,000)	(343,000)
Comprehensive income	$ 4,734,000	$ 10,951,000
Income per common share
Diluted net (loss) income per share, Common Stock (in Dollars per share)	$ 0.03	$ 0.06
Weighted average common shares outstanding
Weighted average shares outstanding of Common Stock Diluted (in Shares)	175,541	174,656
NET (LOSS) INCOME	$ 4,805,000	$ 11,294,000
Weighted average shares outstanding of Common Stock Basic (in Shares)	174,441	173,065
Basic net (loss) income per share, Common Stock (in Dollars per share)	$ 0.03	$ 0.07
Revenues
Total revenues	$ 81,024,000	$ 79,294,000
Cost of revenues
Total cost of revenues	30,431,000	31,392,000
Gross profit	50,593,000	47,902,000
Vaso Corporation and Subsidaries | Managed IT systems and services
Revenues
Total revenues	40,371,000	40,100,000
Vaso Corporation and Subsidaries | Professional sales services
Revenues
Total revenues	37,820,000	36,621,000
Vaso Corporation and Subsidaries | Equipment sales and services
Revenues
Total revenues	2,833,000	2,573,000
Vaso Corporation and Subsidaries | Cost of managed IT systems and services
Cost of revenues
Total cost of revenues	22,712,000	23,871,000
Vaso Corporation and Subsidaries | Cost of equipment sales and services
Cost of revenues
Total cost of revenues	7,021,000	6,912,000
Vaso Corporation and Subsidaries | Cost of equipment sales and services
Cost of revenues
Total cost of revenues	$ 698,000	$ 609,000

Statements of Operations (Paren

Statements of Operations (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Diluted net (loss) income per share, Common Stock	$ (0.77)	$ 0.13

Statements of Changes in Stockh

Statements of Changes in Stockholders’ Deficit - USD ($)	Vaso Corporation and Subsidaries Common Stock	Vaso Corporation and Subsidaries Additional Paid-in Capital	Vaso Corporation and Subsidaries Accumulated deficit	Vaso Corporation and Subsidaries Treasury Stock	Vaso Corporation and Subsidaries Accumulated Other Comprehensive Income (Loss)	Vaso Corporation and Subsidaries	Common Stock	Additional Paid-in Capital	Accumulated deficit	Total
Balance Beginning at Dec. 31, 2021	$ 185,000	$ 63,917,000	$ (51,131,000)	$ (2,000,000)	$ 110,000	$ 11,081,000	$ 250		$ (4,876,287)	$ (4,876,037)
Balance Beginning (in Shares) at Dec. 31, 2021	185,436			(10,308)			2,500,000
Remeasurement of redeemable shares to redemption value									(998,892)	(998,892)
Share-based compensation		35,000				35,000
Foreign currency translation loss					(343,000)	(343,000)
Net loss (Income)			11,294,000			11,294,000			1,623,367	1,623,367
Balance Ending at Dec. 31, 2022	$ 185,000	63,952,000	(39,837,000)	$ (2,000,000)	(233,000)	22,067,000	$ 250		(4,251,812)	(4,251,562)
Balance Ending (in Shares) at Dec. 31, 2022	185,436			(10,308)			2,500,000
Remeasurement of redeemable shares to redemption value									(515,846)	(515,846)
Excise duty in connection with redemption of redeemable shares									(391,544)	(391,544)
Share-based compensation	$ 1,000	47,000				48,000
Share-based compensation (in Shares)	191
Shares withheld for employee tax liability		(6,000)				(6,000)
Foreign currency translation loss					(71,000)	(71,000)
Net loss (Income)			4,805,000			4,805,000			(2,574,642)	(2,574,642)
Balance Ending at Dec. 31, 2023	$ 186,000	$ 63,993,000	$ (35,032,000)	$ (2,000,000)	$ (304,000)	$ 26,843,000	$ 250		$ (7,733,844)	$ (7,733,594)
Balance Ending (in Shares) at Dec. 31, 2023	185,627			(10,308)			2,500,000

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income	$ (2,574,642)	$ 1,623,367
Interest and dividend income on cash and marketable securities held in Trust Account	(429,125)	(1,411,854)
Changes in operating assets and liabilities:
Change in fair value of warrants	(248,953)	(1,997,334)
Prepaid expenses	132,091	228,376
Income taxes payable	(173,486)	216,203
Accounts payable and accrued expenses	2,541,062	580,451
Franchise tax payable	(291,137)	176,875
Due to affiliate		(5,000)
Net cash used in operating activities	(1,044,190)	(588,916)
CASH FLOWS FROM INVESTING ACTIVITIES
Principal deposited in Trust Account	(497,337)
Cash withdrawn from Trust Account in connection with Common Stock redemptions	39,154,420	57,810,572
Cash withdrawal from Trust Account for taxes	410,616	414,836
Net cash provided by investing activities	39,067,699	58,225,408
CASH FLOWS FROM FINANCING ACTIVITIES
Redemption of Common Stock	(39,154,420)	(57,810,572)
Note payable – related party	582,000
Payroll taxes paid by withholding shares
Net cash used in financing activities	(38,572,420)	(57,810,572)
NET CHANGE IN CASH	(548,911)	(174,080)
CASH, BEGINNING OF YEAR	597,306	771,386
CASH, END OF YEAR	48,395	597,306
Supplemental disclosure of noncash activities:
Common stock redemption payable		34,198,758
Excise tax liability	391,544
Vaso Corporation and Subsidaries
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income	4,805,000	11,294,000
Depreciation and amortization	999,000	1,923,000
Deferred income taxes	51,000	(4,788,000)
Loss from investment in EECP Global	206,000	154,000
Provision for credit losses and commission adjustments	66,000	63,000
Share-based compensation	48,000	35,000
Changes in operating assets and liabilities:
Accounts and other receivables	2,062,000	480,000
Due from related parties	(498,000)	(343,000)
Inventories	(22,000)	(416,000)
Deferred commission expense	(36,000)	300,000
Prepaid expenses	(1,271,000)	(103,000)
Other assets, net	(213,000)	(2,422,000)
Accounts payable and accrued expenses	402,000	(521,000)
Accrued commissions	(1,068,000)	950,000
Accrued expenses and other liabilities	(1,549,000)	1,392,000
Sales tax payable	(105,000)	108,000
Deferred revenue	1,397,000	5,838,000
Due to related party	(10,000)	(14,000)
Other long-term liabilities	32,000	486,000
Net cash used in operating activities	5,296,000	14,416,000
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of equipment and software	(731,000)	(566,000)
Purchases of short-term investments	(24,473,000)	(8,000,000)
Redemption of short-term investments	19,547,000	149,000
Net cash provided by investing activities	(5,657,000)	(8,417,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Payroll taxes paid by withholding shares	(6,000)
Repayment of notes payable and finance lease obligations	(128,000)	(230,000)
Net cash used in financing activities	(134,000)	(230,000)
Effect of exchange rate differences on cash and cash equivalents	16,000	27,000
NET CHANGE IN CASH	(479,000)	5,796,000
CASH, BEGINNING OF YEAR	11,821,000	6,025,000
CASH, END OF YEAR	11,342,000	11,821,000
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION
Interest paid	17,000	44,000
Income taxes paid	89,000	48,000
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Initial recognition of operating lease right of use asset and liability	$ 1,174,000	$ 1,396,000

Description of Organization and

Description of Organization and Business Operations	12 Months Ended
	Dec. 31, 2023
Description of Organization and Business Operations [Line Items]
Description of Organization and Business Operations	Note 1 — Description of Organization and Business Operations Achari Ventures Holdings Corp. I (the “Company”) was incorporated in Delaware on January 25, 2021. The Company is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (a “Business Combination”). The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of December 31, 2023, the Company had not commenced any operations. All activity through December 31, 2023 relates to the Company’s formation, its initial public offering (“Initial Public Offering”), and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The registration statement for the Company’s Initial Public Offering was declared effective on October 14, 2021. On October 19, 2021, the Company consummated the Initial Public Offering of 10,000,000 units (“Units”), each of which consisted of one warrant and one share of common stock of the Company, par value $0.0001 per share (“Common Stock” and such shares held by Public Stockholders (defined below), the “Public Shares”) at $10.00 per Unit, generating gross proceeds of $100,000,000, which is discussed in Note 3. The Company has selected December 31 as its fiscal year end. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 7,133,333 warrants (“Private Placement Warrants”) at a price of $0.75 per Private Placement Warrant in a private placement to the Company’s sponsor, Achari Sponsor Holdings I LLC (the “Sponsor”), for gross proceeds of $5,350,000 which is described in Note 4. Offering costs for the Initial Public Offering amounted to $6,101,730, consisting of $2,000,000 of underwriting fees, $3,500,000 of deferred underwriting fees payable (which are held in the Trust Account (defined below)) and $601,730 of other costs. As described in Note 6, the $3,500,000 of deferred underwriting fee payable is contingent upon the consummation of a Business Combination, as further described in the underwriting agreement entered into in connection with the Initial Public Offering. Following the closing of the Initial Public Offering, $101,500,000 ($10.15 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement Warrants was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 -ended -7 The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the agreement to enter into the Business Combination. However, the Company will only complete a Business Combination if the post -transaction The Company will provide the holders of the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.15 per Public Share, plus any pro rata interest then in the Trust Account, net of taxes payable). There will be no redemption rights with respect to the Company’s warrants. All of the Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Company’s Business Combination and in connection with certain amendments to the Company’s Fifth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”). In accordance with Accounting Standards Codification (“ASC”) 480 -10-S99 -20 -10-S99 Redemptions of the Company’s Public Shares may be subject to the satisfaction of conditions, including minimum cash conditions, pursuant to an agreement relating to the Company’s Business Combination. If the Company seeks stockholder approval of the Business Combination, the Company will proceed with a Business Combination if a majority of the shares voted are voted in favor of the Business Combination, or such other vote as required by law or stock exchange rule. If a stockholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Certificate of Incorporation, conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange listing requirements, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction. Notwithstanding the foregoing, the Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Common Stock sold in the Initial Public Offering, without the prior consent of the Company. The Company’s Sponsor, officers and directors (the “Initial Stockholders”) agreed not to propose an amendment to the Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Stockholders with the opportunity to redeem their shares of Common Stock in conjunction with any such amendment. If the Company is unable to complete a Business Combination by July 19, 2024, 33 -month ten -share On December 18, 2023, the Company held a special meeting in lieu of an annual meeting of the Company’s shareholders (the “Special Meeting”), the Company’s shareholders approved (i) a proposal (the “Charter Amendment Proposal”) to amend the Company’s Fourth Amended and Restated Certificate of Incorporation to revise the Company’s then existing extension option, which provided that the Company has the option of extending the period by which the Company must consummate a business combination by up to 12 months, from the original expiration date of January 19, 2023 (the “Original Expiration Date”), to January 19, 2024 (the “Second Amended Extended Date”), to instead provide that the Company will have the option to extend the period by which it must consummate a business combination by an additional six months, from the Second Amended Extended Date, or from January 19, 2024, to July 19, 2024 (the “Third Amended Extended Date”), with such extension option exercisable in six single -month -month th On March 13, 2024, the Company, notified Continental Stock Transfer & Trust Company (the “Trustee”), the trustee of the Company’s trust account (the “Trust Account”), that it was extending the time available to the Company to consummate its initial business combination, from March 19, 2024 to April 19, 2024 (the “Third Extension”), pursuant to and in accordance with the terms of the Company’s Fifth Amended and Restated Certificate of Incorporation and the Company’s Third Amended and Restated Investment Management Trust Agreement (the “Trust Agreement”) the Company deposited $22,037.64 into the Company’s Trust Account. The Third Extension is the third of up to six (6) one -month The Initial Stockholders agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period in connection with the consummation of the Initial Public Offering. However, if the Initial Stockholders decide to acquire Public Shares in addition to their Founder Shares, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to its deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including the Trust Account assets) will be only $10.15 per shares held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third -party At the Special Meeting, holders of 87,380 shares of Common Stock of the Company exercised their right to redeem their shares for cash at an approximate price of $10.90 per share, for an aggregate payment of approximately $952,940, which was withdrawn from the Company’s Trust Account to redeem such shares. Risks and Uncertainties Management is continuing to evaluate the impact of the COVID -19 -19 In order to mitigate the current uncertainty surrounding the implementation of the Inflation Reduction Act of 2022, the Company has decided that in the event that the Proposals are approved and implemented as described in the Definitive Proxy Statement, funds in trust, including any interest thereon, will not be used to pay for any excise tax liabilities with respect to any future redemptions that occur after December 31, 2022, and prior to or in connection with a Business Combination or liquidation of the Company and which result from the implementation of the Inflation Reduction Act of 2022. Liquidity and Capital Resources As of December 31, 2023, the Company had cash of $48,395 in its operating bank account and $6,049,745 of cash held in the Trust Account to be used for a Business Combination or to repurchase or redeem its Common Stock in connection therewith. As of December 31, 2023, approximately $429,125 of the amount on deposit in the Trust Account represented interest and dividend income from investments, which is available to pay the Company’s tax obligations. The Company has until July 19, 2024 (which is 33 months from the October 19, 2021 closing of the Company’s Initial Public Offering) if the Company exercises each of its six monthly Extension Options. Until the consummation of a Business Combination, the Company is and will continue to use the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to acquire, and structuring, negotiating and consummating the Business Combination. The Company may need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company’s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company’s working capital needs. Accordingly, the Company may not be able to obtain additional financing. Management has determined that the mandatory liquidation, should a business combination not occur, and potential subsequent dissolution and liquidity condition described in Note 1 of the financial statements, raises substantial doubt about the Company’s ability to continue as a going concern. As described in Note 6, the $3,500,000 of deferred underwriting fee payable is contingent upon the consummation of a Business Combination subject to the terms of the underwriting agreement. It is uncertain that the Company will be able to consummate a Business Combination by the specified period. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time, which is considered to be one year from the issuance date of the financial statements. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
Vaso Corporation and Subsidaries [Member]
Description of Organization and Business Operations [Line Items]
Description of Organization and Business Operations	NOTE A — DESCRIPTION OF BUSINESS Vaso Corporation was incorporated in Delaware in July 1987. For most of its history, the Company was a single -product ® Overview Vaso Corporation principally operates in three distinct business segments in the healthcare equipment and information technology industries. We manage and evaluate our operations, and report our financial results, through these three business segments. • -owned • -owned • -owned VasoTechnology VasoTechnology, Inc. was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC (collectively, “NetWolves”). It currently consists of a managed network and security service division, NetWolves, and a healthcare IT application VAR (value added reseller) division, VasoHealthcare IT. In June 2014, the Company began its IT segment business by executing the Value Added Reseller Agreement (“VAR Agreement”) with GEHC to become a national value added reseller of GEHC Digital’s software solutions such as Picture Archiving and Communication System (“PACS”), Radiology Information System (“RIS”), and related services, including implementation, training, management and support. This business focuses primarily on customer segments currently served by VasoHealthcare on behalf of GEHC. A new wholly owned subsidiary, VasoHealthcare IT Corp. (“VHC IT”), was formed to conduct the healthcare IT business. The VAR Agreement with GEHC was terminated in 2021. In May 2015, the Company further expanded its IT segment business by acquiring NetWolves. NetWolves designs and delivers multi -network -technology -source -time VasoHealthcare In May 2010, the Company launched its Professional Sales Service business through a wholly -owned VasoMedical The proprietary medical equipment business under VasoMedical traces back to 1995 when the Company began the proprietary Enhanced External Counterpulsation (EECP ® Over the last 10+ years the Company’s Equipment business has been significantly expanded from the original EECP ® -only ® -parameter ® ® In April 2014, the Company entered into a cooperation agreement with Chongqing PSK -Health -Tech -owned three -year Achari Business Combination Agreement As previously announced, the Company entered into a business combination agreement (the “Business Combination Agreement”), dated as of December 6, 2023, with Achari Ventures Holdings Corp. I, a Delaware corporation (“Achari”) (NASDAQ: AVHI), and Achari Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Achari (“Merger Sub”). The Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving as a wholly owned subsidiary of Achari. Upon the closing of the Business Combination Agreement (the “Closing”), we anticipate that Achari will change its name to “Vaso Holdings Corp.” or an alternative name chosen by the Company and reasonably acceptable to Achari (“New Vaso”). The Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to collectively as the “Business Combination”. Upon the Closing, New Vaso would have authorized shares of Class A common stock and Class B common stock. The Business Combination Agreement establishes a pro forma equity value of the Company at approximately $176 million, at $10.00 per share of Class A common stock. As such, we believe that the current Vaso stockholders would receive approximately 17.6 million shares of Class A common stock and the current Achari shareholders would maintain between 500 thousand and 750 thousand shares of Class A common stock depending on Achari’s unpaid expenses at the Closing and presuming the redemption of all outstanding public shares of Achari on or prior to the Closing. In addition, current Achari warrant holders would have outstanding warrants to purchase a minimum of 8.25 million shares of Class A common stock at an exercise price of $11.50 per share. No shares of Class B common stock are expected to be outstanding immediately after the Business Combination. The Boards of Directors of Vaso and Achari have each approved the Business Combination, the consummation of which is subject to various customary closing conditions, including the filing and effectiveness of a Registration Statement on Form S -4

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Summary of Significant Accounting Policies [Line Items]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Emerging Growth Company The Company is an emerging growth company as defined in Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), which exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non -emerging This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all short -term Marketable Securities Held in the Trust Account At December 31, 2023 and 2022, substantially all of the assets held in the Trust Account were held in cash and mutual fund that invests in U.S. Treasury securities respectively. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in Interest and dividend income on cash and marketable securities held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. At December 31, 2023 and 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the Financial Accounting Standards Board (“FASB”) ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short -term Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes” (“ASC 740”), which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2023 and 2022. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the years ended December 31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. (see Note 10) Common Stock Subject to Possible Redemption The Company accounts for its Common Stock subject to possible redemption in accordance with the guidance in ASC 480, “Distinguishing Liabilities from Equity” (“ASC 480”). Shares of Common Stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable Common Stock (including Common Stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times Common Stock is classified as stockholders’ equity. The Company’s Common Stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at December 31, 2023, 550,941 shares of Common Stock subject to possible redemption are presented as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Common Stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable Common Stock are affected by charges against additional paid -in At December 31, 2023, the Common Stock subject to possible redemption reflected in the balance sheet is reconciled in the following table: Gross proceeds $ 100,000,000 Less: Proceeds allocated to Public Warrants (11,900,000 ) Common Stock issuance costs (5,322,219 ) Plus: Remeasurement of carrying value to redemption value 18,722,219 Common Stock subject to possible redemption as of December 31, 2021 101,500,000 Less: Redemption of Common Stock (57,810,572 ) Common Stock redemption payable (34,198,758 ) Plus: Remeasurement of carrying value to redemption value (net) 998,892 Common Stock subject to possible redemption as of December 31, 2022 10,489,562 Redemption of Common Stock (4,955,663 ) Plus: Remeasurement of carrying value to redemption value 515,846 Common Stock subject to possible redemption as of December 31, 2023 $ 6,049,745 Net (Loss) Income per Common Stock The Company has one class of shares. Public Warrants (see Note 3) and Private Placement Warrants (see Note 4) to purchase 12,850,000 shares of Common Stock at $11.50 per share were issued on October 19, 2021. As of December 31, 2023, no Public Warrants or Private Placement Warrants have been exercised. The 12,850,000 potential shares of Common Stock for outstanding Public Warrants and Private Placement Warrants to purchase the Common Stock were excluded from diluted earnings per share for the year ended December 31, 2023 because they are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net (loss) income per share of Common Stock is the same as basic net (loss) income per shares of Common Stock for the period. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net (loss) income per share for each class of stock. For the For the Basic and diluted net (loss) income per share: Numerator: Allocation of net (loss) income $ (2,574,642 ) $ 1,623,367 Denominator: Weighted average shares outstanding 3,336,745 12,278,562 Basic and diluted net (loss) income per share $ (0.77 ) $ 0.13 Accounting for Warrants The Company accounts for warrants as either equity -classified -classified classification. This assessment, which requires the use of professional judgment, was conducted at the time of warrant issuance and as of each subsequent period end date while the instruments are outstanding. Management has concluded that the Public Warrants qualify for equity accounting treatment and the Private Placement Warrants issued pursuant to the warrant agreement qualify for liability accounting treatment. Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020 -06 -20 -40 -06 -linked -06 The Company has reviewed other recent accounting pronouncements and concluded that they are either not applicable to the Company or no material effect is expected on the financial statements as a result of future adoption.
Vaso Corporation and Subsidaries [Member]
Summary of Significant Accounting Policies [Line Items]
Summary of Significant Accounting Policies	NOTE C — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies consistently applied in the preparation of the consolidated financial statements are as follows: Principles of Consolidation The consolidated financial statements include the accounts of Vaso Corporation, its wholly -owned Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions relate to estimates of commission adjustments due to order cancellations, collectability of accounts receivable, the realizability of deferred tax assets, stock -based Revenue Recognition In May 2014, the FASB issued ASU 2014 -09 -09 -step • Revenue relating to recurring managed network and voice services provided by NetWolves, for which the customer has unlimited access to such services throughout the contract term, are thus recognized as provided on a monthly basis (“over time”). Non -recurring -implementation -ready • Commission revenue is recognized when the underlying equipment has been delivered by GEHC and accepted at the customer site in accordance with the terms of the specific sales agreement (“point in time”). • In the United States, we recognized revenue from the sale of our medical equipment in the period in which we deliver the product to the customer (“point in time”). Revenue from the sale of our medical equipment to international markets is recognized upon shipment of the product to a common carrier, as are supplies, accessories and spare parts delivered in both domestic and international markets (“point in time”). Revenue from the provision of ARCS ® -billed Disaggregation of Revenue The following tables present revenues disaggregated by our business operations and timing of revenue recognition: (in thousands) Year Ended December 31, 2023 Year Ended December 31, 2022 IT Professional Equipment Total IT Professional Equipment Total Network services $ 35,673 $ — $ — $ 35,673 $ 35,833 $ — $ — $ 35,833 Software sales and support 4,698 — — 4,698 4,267 — — 4,267 Commissions — 37,820 — 37,820 — 36,621 — 36,621 Medical equipment sales — — 2,708 2,708 — — 2,450 2,450 Medical equipment service — — 125 125 — — 123 123 $ 40,371 $ 37,820 $ 2,833 $ 81,024 $ 40,100 $ 36,621 $ 2,573 $ 79,294 Year Ended December 31, 2023 Year Ended December 31, 2022 IT Professional Equipment Total IT Professional Equipment Total Revenue recognized over $ 37,223 $ — $ 600 $ 37,823 $ 37,089 $ — $ 325 $ 37,414 Revenue recognized at a point in time 3,148 37,820 2,233 43,201 3,011 36,621 2,248 41,880 $ 40,371 $ 37,820 $ 2,833 $ 81,024 $ 40,100 $ 36,621 $ 2,573 $ 79,294 Transaction Price Allocated to Remaining Performance Obligations As of December 31, 2023, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $95 million, of which we expect to recognize revenue as follows: (in thousands) Fiscal years of revenue recognition 2024 2025 2026 Thereafter Unfulfilled performance obligations $ 44,667 $ 19,861 $ 6,240 $ 23,918 As of December 31, 2022, the aggregate amount of transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied) for executed contracts approximated $91 million. Contract Balances Contract receivables include trade receivables, net and long -term -based -live -live -live In our VasoHealthcare business, we bill a portion of commissions on the orders we booked in advance of delivery of the underlying equipment. Such amounts aggregated approximately $32,194,000 and $30,794,000 at December 31, 2023 and 2022, respectively, and are classified in our consolidated balance sheets into current or long -term In our VasoMedical business, we bill amounts for post -delivery -term The following table summarizes the Company’s contract receivable and contract liability balances: (in thousands) 2023 2022 Contract receivables – January 1 15,306 15,474 Contract receivables – December 31 13,398 15,306 Increase (decrease) (1,909 ) (168 ) Contract liabilities – January 1 33,861 26,890 Contract liabilities – December 31 33,589 33,861 Increase (decrease) (272 ) 6,971 The decrease in contract receivables and liabilities in 2023 is due primarily to increased estimate of allowance for commission adjustments in our VasoHealthcare business. During the years ended December 31, 2023 and 2022, we recognized approximately $9.2 million and $9.1 million, respectively, of revenues that were included in our contract liability balance at the beginning of such periods. Costs to Obtain or Fulfill a Contract Topic 606 requires that incremental costs of obtaining a contract are recognized as an asset and amortized to expense in a pattern that matches the timing of the revenue recognition of the related contract. We have determined the only significant incremental costs incurred to obtain contracts with customers within the scope of Topic 606 are certain sales commissions paid to associates. In addition, the Company elected the practical expedient to recognize the incremental costs of obtaining a contract when incurred for contracts where the amortization period for the asset the Company would otherwise have recognized is one year or less. Under Topic 606, sales commissions applicable to service contracts exceeding one year have been capitalized and amortized ratably over the term of the contract. In our VHC IT business, commissions allocable to multi -year -year -contract -year -live At December 31, 2023 and 2022, our consolidated balance sheets include approximately $7,106,000 and $7,113,000, respectively, in capitalized sales commissions — primarily in our professional sales services segment — to be expensed in future periods, of which $3,285,000 and $3,249,000, respectively, is recorded in deferred commission expense and $3,821,000 and $3,864,000, respectively, representing the long -term Significant Judgments when Applying Topic 606 Contract transaction price is allocated to performance obligations using estimated stand -alone -alone -alone -alone -alone -alone Certain revenue we record in our professional sales service segment contains an estimate for variable consideration. Due to the tiered structure of our commission rate, which increases as annual targets are achieved, under Topic 606 we record revenue and deferred revenue at the rate we expect to be achieved by year end. We base our estimate of variable consideration on historical results of previous years’ achievement under the GEHC agreement. Such estimate is reviewed each quarter and adjusted as necessary. In addition, the Company records commissions for arranging financing at an estimated rate which is subject to later revision based on certain factors. The Company recognized increases (decreases) in revenue associated with revisions to variable consideration for previously completed performance obligations of $3,000 and $(5,000) for the years ended December 31, 2023 and 2022 respectively. The Company also records commission adjustments to contract liabilities in its professional sales service segment based on estimates of future order cancellations. Such cancellations also result in adjustments to the related capitalized cost to obtain or fulfill a contract. Shipping and Handling Costs All shipping and handling expenses are charged to cost of sales. Amounts billed to customers related to shipping and handling costs are included as a component of sales. Research and Development Research and development costs attributable to development are expensed as incurred. Share-Based Compensation The Company complies with ASC Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires all companies to recognize the cost of services received in exchange for equity instruments to be recognized in the financial statements based on their grant date fair values. The Company applies an estimated forfeiture rate to the grant date fair value to determine the annual compensation cost of share -based -employees During the year ended December 31, 2023, the Company granted 225,000 restricted shares of common stock valued at $50,000 to employees. The shares vest over five years from the grant date. The total fair value of shares vested during the year ended December 31, 2023 was $27,000 for officers and $24,000 for employees. The weighted average grant date fair value of shares granted during the year ended December 31, 2023 was $0.22 per share, based on the closing price as of the grant date. During the year ended December 31, 2022, the Company granted 1,050,000 restricted shares of common stock valued at $115,000 to employees. The shares vest over three and five years from the grant date. The total fair value of shares vested during the year ended December 31, 2022 was $23,000 for officers and $4,000 for employees. The weighted average grant date fair value of shares granted during the year ended December 31, 2022 was $0.11 per share, based on the closing price as of the grant date. The Company did not grant any stock options during the years ended December 31, 2023 or 2022, nor were any options exercised during such periods. No options were outstanding at December 31, 2023 or 2022. Share -based -based -average Cash and Cash Equivalents Cash and cash equivalents represent cash and short -term Short term investments The Company’s short -term -month -to-maturity -for-sale -term Financial Instruments The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows: Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model -derived Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The carrying amount of assets and liabilities including cash and cash equivalents, short -term -measured The following table presents information about the Company’s assets measured at fair value as of December 31, 2023 and 2022: Quoted Prices Significant Significant Balance as of Assets Cash equivalents invested in money market funds and treasury bills $ 10,522 $ — $ — $ 10,522 Bank deposits (included in short term investments) 424 424 $ 10,946 $ — $ — $ 10,946 Quoted Prices Significant Significant Balance as of Assets Cash equivalents invested in money market funds $ 7,934 $ — $ — $ 7,934 Bank deposits (included in short term investments) 433 433 $ 8,367 $ — $ — $ 8,367 Accounts Receivable, net The Company’s accounts receivable are due from customers to whom we sell our products and services, distributors engaged in the distribution of our products and from GEHC. Credit is extended based on evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are generally due 30 to 90 days from shipment and services provided and are stated at amounts due from customers net of allowances for doubtful accounts, returns, term discounts and other allowances. Accounts that are outstanding longer than the contractual payment terms are considered past due. Estimates are used in determining the allowance for doubtful accounts based on the Company’s historical collections experience, current trends, credit policy and a percentage of its accounts receivable by aging category. In determining these percentages, the Company reviews historical write -offs The changes in the Company’s allowance for doubtful accounts and commission adjustments are as follows: (in thousands) Year ended December 31, 2023 2022 Beginning Balance $ 6,947 $ 5,804 Provision for losses on accounts receivable 66 63 Direct write-offs, net of recoveries (60 ) (159 ) Commission adjustments 2,755 1,239 Ending Balance $ 9,708 $ 6,947 Concentrations of Credit Risk We market our equipment and IT software solutions principally to hospitals, diagnostic imaging centers and physician private practices. We perform credit evaluations of our customers’ financial condition and, as a result, believe that our receivable credit risk exposure is limited. For the years ended December 31, 2023 and 2022, no customer in our equipment or IT segment accounted for 10% or more of revenues or accounts receivable. In our professional sales service segment, 100% of our revenues and accounts receivable are with GEHC; however, we believe this risk is acceptable based on GEHC’s financial position and our long history of doing business with GEHC. The Company maintains cash balances in certain U.S. financial institutions which exceed the Federal Depository Insurance Corporation (“FDIC”) coverage of $250,000 by approximately $10,054,000. The Company has not experienced any losses on these accounts and believes it is not subject to any significant credit risk on these accounts. In addition, the FDIC does not insure the Company’s foreign bank balances, which aggregated approximately $467,000 and $1,234,000 at December 31, 2023 and 2022, respectively. Inventories The Company values inventories in the equipment segment at the lower of cost or net realizable value, with cost being determined on a first -in -out In our IT Segment, we purchase computer hardware and software for specific customer requirements and value such inventories using the specific identification method. Property and Equipment Property and equipment, including assets under finance leases, are stated at cost less accumulated depreciation and amortization. Major improvements are capitalized and minor replacements, maintenance and repairs are charged to expense as incurred. Upon retirement or disposal of assets, the cost and related accumulated depreciation are removed from the consolidated balance sheets. Depreciation is expensed over the estimated useful lives of the assets, which range from two eight -line Impairment of Long-lived Assets The Company reviews the recoverability of all long -lived -lived No Goodwill and Intangible Assets Goodwill represents the excess of cost over the fair value of net assets of businesses acquired. The Company accounts for goodwill under the guidance of the ASC Topic 350, “Intangibles: Goodwill and Other”. Goodwill acquired in a purchase business combination and determined to have an indefinite useful life is not amortized, but instead tested for impairment, at least annually, in accordance with this guidance. The recoverability of goodwill is subject to an annual impairment test or whenever an event occurs or circumstances change that would more likely than not result in an impairment. The impairment test is based on the estimated fair value of the underlying businesses and performed in the fourth quarter of each year. We perform either a quantitative or qualitative assessment to assess if the fair value of the respective reporting unit exceeds its carrying value. The qualitative goodwill impairment assessment requires evaluating factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. As part of our goodwill qualitative assessment process for our two applicable reporting units, when utilized, we evaluate various factors that are specific to the reporting unit as well as industry and macroeconomic factors in order to determine whether it is reasonably likely to have a material impact on the fair value of our reporting units. Examples of the factors that are considered include the results of the most recent impairment test, current forecasts, and changes in the strategic outlook or organizational structure of the reporting units. The financial forecasts of the reporting units are compared to the forecasts used in the prior year analysis to determine if management expectations for the business have changed. When performing the quantitative assessment to calculate the fair value of a reporting unit, we consider both comparative market multiples as well as estimated discounted cash flows for the reporting unit. The significant estimates and assumptions include, but are not limited to, revenue growth rates, operating margins, and future economic and market conditions. The discount rates are based upon industry weighted average cost of capital ranges. As a supplement, we conduct additional sensitivity analysis to assess the risk for potential impairment based upon changes in the key assumptions such as the discount rate, expected long -term Based upon the completion of our annual test as of December 31, 2023 and 2022, we determined that there was no impairment of goodwill and that the applicable reporting units’ estimated fair values were substantially in excess of their carrying amounts. Intangible assets consist of the value of customer contracts and relationships, patent and technology costs, and software. The cost of significant customer -related -line five ten No Deferred Revenue Amounts billable under the agreement with GEHC in advance of delivery of the underlying equipment are recorded initially as deferred revenue, and commission revenue is subsequently recognized as customer acceptance of such equipment is reported to us by GEHC. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized. In our equipment segment, we record revenue on extended service contracts ratably over the term of the related service contracts. Income Taxes Deferred income taxes are recognized for temporary differences between financial statement and income tax bases of assets and liabilities and loss carry -forwards The Company also complies with the provisions of ASC Topic 740, “Income Taxes”, which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more -likely-than-not No Foreign Currency Translation Gain (Loss) and Comprehensive Income In the country in which the Company operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date. Equity accounts are translated at historical rates except for the changes in accumulated deficit during the year as the result of the income statement translation process. Revenues and expenses and cash flows are translated using a weighted average exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income (loss) on the accompanying consolidated balance sheets. For the years ended December 31, 2023 and 2022, other comprehensive income includes losses of $71,000 and $343,000, respectively, which were entirely from foreign currency translation loss. Net Income Per Common Share Basic income per common share is based on the weighted average number of common shares outstanding, including vested restricted shares, without consideration of potential common stock. Diluted earnings per common share is based on the weighted average number of common and potential dilutive common shares outstanding. Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares. A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows: (in thousands) Year ended December 31, 2023 2022 Basic weighted average shares outstanding 174,441 173,065 Dilutive effect of unvested restricted shares 1,100 1,591 Diluted weighted average shares outstanding 175,541 174,656 No Recently Adopted Accounting Standards On January 1, 2023 the Company adopted ASU No. 2021 -08 -20 On January 1, 2023 the Company adopted ASU No. 2022 -04 -50 obligations are recorded in the balance sheet, and a rollforward of the obligations. As the Company does not engage in supplier finance programs, the adoption of this standard did not have a material impact on its Consolidated Financial Statements as of January 1, 2023. Recently Issued Accounting Standards To Be Adopted The Company continually assesses any new accounting pronouncements to determine their applicability to the Company. Where it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequence of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change. New pronouncements assessed by the Company recently are discussed below: In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023 -09 In November 2023, the FASB issued ASU 2023 -07

Initial Public Offering

Initial Public Offering	12 Months Ended
	Dec. 31, 2023
Initial Public Offering [Abstract]
Initial Public Offering	Note 3 — Initial Public Offering Pursuant to the Initial Public Offering, the Company sold 10,000,000 Units at a price of $10.00 per Unit. Each Unit consists of one Public Share, and one redeemable warrant (each, a “Public Warrant”). Each Public Warrant entitles the holder to purchase three quarters of one share of Common Stock at a price of $11.50 per share, subject to adjustment (see Note 7).

Private Placement Warrants

Private Placement Warrants	12 Months Ended
	Dec. 31, 2023
Private Placement Warrants [Abstract]
Private Placement Warrants	Note 4 — Private Placement Warrants On October 19, 2021, simultaneously with the consummation of the Initial Public Offering, the Company consummated the issuance and sale of 7,133,333 Private Placements Warrants in a private placement transaction at a price of $0.75 per Private Placement Warrant, generating gross proceeds of $5,350,000. Each whole Private Placement Warrant will be exercisable to purchase three quarters of one share of Common Stock at a price of $11.50 per share. A portion of the proceeds from the Private Placement Warrants will be added to the proceeds from the Initial Public Offering to be held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Placement Warrants and all underlying securities will be worthless.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Line Items]
Related Party Transactions	Note 5 — Related Party Transactions Founder Shares In February 2021, the Sponsor paid an aggregate purchase price of $25,000, or approximately $0.009 per share, in consideration of 2,156,250 shares of Common Stock to cover certain expenses of the Company (the “Founder Shares”). In June 2021, the Company effected a 1.3333 -for-1 -allotment -allotment The Sponsor agreed that it will not transfer, assign or sell any Founder Shares until (1) with respect to 50% of the shares, the earlier of six months after the date of the consummation of the Business Combination and the date on which the closing price of the Company’s Common Stock exceeds $12.50 per share (as adjusted for share splits, share capitalizations, reorganizations and recapitalizations) for any 20 trading days within any 30 -trading Related Party Loans On January 25, 2021, the Company issued an unsecured promissory note to the Sponsor (the “Promissory Note”), pursuant to which the Company borrowed up to an aggregate principal amount of $300,000. The Promissory Note was non -interest On July 18, 2023, the Company and the Sponsor entered into a non -interest-bearing $0 -related In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $0.75 per warrant. The warrants would be identical to the Private Placement Warrants. As of December 31, 2023 and 2022, there were no
Vaso Corporation and Subsidaries [Member]
Related Party Transactions [Line Items]
Related Party Transactions	NOTE L — RELATED-PARTY TRANSACTIONS David Lieberman, a practicing attorney in the State of New York, serves as Vice Chairman of the Board of Directors. Until July 2022, he was a senior partner at the law firm of Beckman Lieberman and Associates, LLP, which performed certain legal services for the Company. Fees of approximately $0 and $95,000 were billed by the firm for the years ended December 31, 2023 and 2022, respectively, at which dates no amounts were outstanding.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies [Line Items]
Commitments and Contingencies	Note 6 — Commitments and Contingencies Registration Rights The holders of the Founder Shares, Private Placement Warrants and any warrants issued upon conversion of Working Capital Loans (and any shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of working capital loans) are entitled to registration rights pursuant to an agreement entered into in connection with the Company’s Initial Public Offering requiring the Company to register such securities for resale. The holders of a majority of these securities are entitled to make up to three demands, except short form demands, that the Company register such securities. In addition, the holders have certain “piggyback” registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriters a 45 -day -allotments -day The underwriters were paid a cash underwriting discount of $0.20 per Unit, or $2,000,000 in the aggregate at the closing of the Initial Public Offering. In addition, the underwriters are entitled to a deferred underwriting commissions of $0.35 per Unit, or $3,500,000 from the closing of the Initial Public Offering. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely if the Company completes a Business Combination, subject to the terms of the underwriting agreement.
Vaso Corporation and Subsidaries [Member]
Commitments and Contingencies [Line Items]
Commitments and Contingencies	NOTE S — COMMITMENTS AND CONTINGENCIES Sales representation agreement In October 2022, the Company concluded an amendment of the GEHC Agreement with GEHC, originally signed on May 19, 2010 and previously extended in 2012, 2015 and 2017. The amendment extended the term of the original agreement, which began on July 1, 2010, through December 31, 2026, subject to early termination by GEHC without cause with certain conditions. Under the agreement, VasoHealthcare is the exclusive representative for the sale of select GEHC diagnostic imaging and ultrasound products to specific market accounts in the 48 contiguous states of the United States and the District of Columbia. The circumstances under which early termination of the agreement may occur with cause include: not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and not meeting various legal and GEHC policy requirements. The Company met all the contractual conditions in 2023. Employment Agreements On May 10, 2019, the Company modified its Employment Agreement with its President and Chief Executive Officer, Dr. Jun Ma, to provide for a five -year -term On December 31, 2023, the Company executed an Employment Agreement with the President of its VasoHealthcare subsidiary, Ms. Jane Moen, to provide for a twenty -seven -term Licensing and Support Service Agreement In December 2023, NetWolves extended the licensing and support service agreement of its billing system for an additional year, to expire December 2024. The agreement provides for monthly recurring charges based on a percentage of billed revenues using these services, which charges aggregated approximately $337,000 and $339,000 for the years ended December 31, 2023 and 2022, respectively. Litigation The Company is currently, and has been in the past, a party to various routine legal proceedings, primarily employee related matters, incident to the ordinary course of business. The Company believes that the outcome of all such pending legal proceedings in the aggregate is unlikely to have a material adverse effect on the business or consolidated financial condition of the Company. Foreign operations During the years ended December 31, 2023 and 2022, the Company had and continues to have operations in China. Operating transactions in China are denominated in the Chinese currency called RMB or CNY, which is not freely convertible into foreign currencies. Operating internationally involves additional risks relating to such things as currency exchange rates, different legal and regulatory environments, political, economic risks relating to the stability or predictability of foreign governments, differences in the manner in which different cultures do business, difficulties in staffing and managing foreign operations, differences in financial reporting, operating difficulties, and other factors. Commercial law is still developing in China and there are limited legal precedents to follow in commercial transactions. There are many tax jurisdictions, each of which may have changing tax laws. Applicable taxes include value added taxes (“VAT”), Enterprise Income Tax, and social (payroll) taxes. Regulations are often unclear. Tax declarations (reports) are subject to review and taxing authorities may impose fines, penalties and interest. These facts create risks in China.

Stockholders_ Deficit

Stockholders’ Deficit	12 Months Ended
	Dec. 31, 2023
Stockholders’ Deficit [Line Items]
Stockholders’ Deficit	Note 7 — Stockholders’ Deficit Common Stock Preferred Stock no Public Warrants 30 one five th “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the foregoing, if a registration statement covering the shares issuable upon exercise of the warrants is not effective within a specified period following the consummation of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. Once the warrants become exercisable, the Company may redeem the Public Warrants: • • • • 30 • -trading If and when the warrants become redeemable by the Company, the Company may not exercise its redemption right if the issuance of shares of Common Stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or the Company is unable to effect such registration or qualification. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The exercise price and number of shares of Common Stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuance of Common Stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. As of December 31, 2023 and 2022, there were 10,000,000 of Public Warrants outstanding.
Vaso Corporation and Subsidaries [Member]
Stockholders’ Deficit [Line Items]
Stockholders’ Deficit	NOTE P — STOCKHOLDERS’ EQUITY Chinese subsidiaries dividends and statutory reserves The payment of dividends by entities organized in China is subject to limitations. In particular, regulations in China currently permit payment of dividends only out of accumulated profits as determined in accordance with People’s Republic of China (“PRC”) accounting standards and regulations. Based on PRC accounting standards, our Chinese subsidiaries are also required to set aside at least 10% of after -tax -tax

Warrant Liabilities

Warrant Liabilities	12 Months Ended
	Dec. 31, 2023
Warrant Liabilities [Abstract]
Warrant Liabilities	Note 8 — Warrant Liabilities Private Warrants — The Private Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Warrants and the shares of Common Stock issuable upon the exercise of the Private Warrants are not transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Warrants are exercisable for cash or on a cashless basis, at the holder’s option, and be non -redeemable The exercise price and number of shares of Common Stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuances of shares of Common Stock at a price below their respective exercise prices. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. In addition, if the Company issues additional shares of Common Stock or equity -linked -linked As of December 31, 2023 and 2022, there were 7,133,333 of private warrants outstanding.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2023
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 9 — Fair Value Measurements The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Unobservable inputs based on an assessment of the assumptions that market participants would use in pricing the asset or liability. At December 31, 2023, the investments held in the Trust Account were held in a cash. The following tables present information about the Company’s liabilities that are measured at fair value on a recurring basis at December 31, 2023 and 2022 and indicate the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: December 31, 2023 Level Quoted Significant Significant Assets: Cash and marketable securities held in Trust Account 1 $ 6,049,745 $ — $ — Warrant Liability-Private Placement Warrants 3 $ — $ — $ 107,713 December 31, 2022 Level Quoted (Level 1) Significant Inputs (Level 2) Significant Inputs (Level 3) Assets: Marketable Securities 1 $ 44,688,320 $ — $ — Warrant Liability-Private Placement Warrants 3 $ — $ — $ 356,666 The Company utilizes a Monte Carlo simulation model to value the warrants at each reporting period, with changes in fair value recognized in the statements of operations. The estimated fair value of the warrant liability is determined using Level 3 inputs. Inherent in a Monte Carlo pricing model are assumptions related to expected share -price -free -free -coupon The following table provides quantitative information regarding Level 3 fair value measurements at December 31, 2023 and 2022: December 31, December 31, Stock Price $ 10.89 $ 10.22 Exercise Price $ 11.50 $ 11.50 Term (years) 0.96 2.91 Volatility 1.15 % 0.20 % Risk Free Rate 4.77 % 4.24 % Dividend Yield 0.00 % 0.00 % The following table presents the changes in the fair value of Level 3 warrant labilities: Private Fair value as of October 19, 2021 (IPO) $ 9,986,666 Change in fair value (7,632,666 ) Fair value as of December 31, 2021 2,354,000 Change in fair value (1,997,334 ) Fair value as of December 31, 2022 356,666 Change in fair value (248,953 ) Fair value as of December 31, 2023 $ 107,713

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Taxes [Line Items]
Income Taxes	Note 10 — Income Taxes The total Income tax provision is comprised of the following for the years ended December 31, 2023 and 2022: December 31, December 31, Federal Current $ 72,980 $ 216,203 Deferred (688,629 ) (246,333 ) State and local Current — — Deferred — — Change in valuation allowance 688,629 246,333 Income tax provision $ 72,980 $ 216,203 Deferred tax assets and liabilities and assets are determined based on the difference between the financial statement and tax basis of assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse. The net deferred tax assets in the accompanying balance sheets included the following components: December 31, December 31, Deferred tax assets Start-up costs $ 688,629 $ 308,347 Net operating loss carryforward — — Total deferred tax asset 688,629 308,347 Valuation allowance (688,629 ) (308,347 ) Deferred tax asset net of allowance $ — $ — The Company’s federal net operating loss carryforward as of December 31, 2023 and 2022 amounted to $0. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, Management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. For the years ended December 31, 2023 and 2022, the change in valuation allowance was $688,629 and $308,347, respectively. A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate (approximate) is as follows: December 31, December 31, Statutory federal income tax rate 21.00 % 21.00 % State taxes, net of federal tax benefit 0.00 % 0.00 % Change in fair value of warrants 9.95 % (22.80 )% Warrant issuance costs 0.00 % 0.00 % Valuation allowance (27.53 )% 13.29 % Income tax provision expense (3.42 )% 11.49 % The tax provision differs from the statutory rate of 21% due to the change in fair value of warrants and the valuation allowance.
Vaso Corporation and Subsidaries [Member]
Income Taxes [Line Items]
Income Taxes	NOTE R — INCOME TAXES The following is a geographical breakdown of income before the provision for income taxes: (in thousands) Year ended December 31, 2023 2022 Domestic $ 5,085 $ 6,244 Foreign (180 ) 307 Income before provision for income taxes $ 4,905 $ 6,551 The provision for income taxes consisted of the following: (in thousands) Year ended December 31, 2023 2022 Current provision (benefit) Federal $ — $ — State 50 36 Foreign (1 ) 9 Total current provision (benefit) 49 45 Deferred provision (benefit) Federal 40 (3,724 ) State 11 (1,064 ) Foreign — — Total deferred provision (benefit) 51 (4,788 ) Total income tax provision (benefit) $ 100 $ (4,743 ) Effective income tax rate 2.04 % (72.40 )% The income tax expense of $100,000 for the year ended December 31, 2023 was due $50,000 in state income taxes and a $51,000 reduction in deferred tax assets, offset by a $1,000 foreign tax benefit. The income tax benefit of $4,743,000 for the year ended December 31, 2022 was due to the partial release of deferred tax asset valuation allowance, offset by $36,000 in state income taxes and $9,000 in foreign taxes. The following is a reconciliation of the effective income tax rate to the federal statutory rate: For the year ended December 31, 2023 December 31, 2022 % % Federal statutory rate 21.00 21.00 State income taxes 6.19 6.11 Change in valuation allowance relating to operations (17.96 ) (92.63 ) Foreign tax rate differential (2.71 ) (0.81 ) R&D credit 1.87 0.58 Nondeductible expenses 0.71 0.22 Other (7.06 ) (6.87 ) 2.04 (72.40 ) The effective tax rate increased mainly due to the impact of the partial release of the deferred tax asset valuation allowance in 2022. As of December 31, 2023, the recorded deferred tax assets were $11,547,000, reflecting a decrease of $459,000 during the year ended December 31, 2023, which was offset by a valuation allowance of $3,663,000, reflecting a decrease of $880,000. The components of our deferred tax assets and liabilities are summarized as follows: (in thousands) December 31, 2023 December 31, 2022 Deferred Tax Assets: Net operating loss carryforwards $ 6,796 $ 8,367 Amortization 590 328 Stock-based compensation 4 7 Allowance for doubtful accounts 100 99 Reserve for slow moving inventory 46 46 Tax credits 324 416 Expense accruals 855 908 Capitalized R&D 13 — Deferred revenue 2,819 1,835 Total gross deferred taxes 11,547 12,006 Valuation allowance (3,663 ) (4,543 ) Net deferred tax assets 7,884 7,463 Deferred Tax Liabilities: Deferred commissions (701 ) (464 ) Goodwill (2,221 ) (1,962 ) Depreciation (7 ) (30 ) Total deferred tax liabilities (2,929 ) (2,456 ) Total deferred tax assets (liabilities) 4,955 5,007 Recorded as: Non-current deferred tax assets 4,955 5,007 Non-current deferred tax liabilities — — Total deferred tax assets (liabilities) $ 4,955 $ 5,007 The activity in the valuation allowance is set forth below: (in thousands) 2023 2022 Valuation allowance, January 1, $ 4,543 $ 10,769 Partial release of allowance — (4,840 ) Change in valuation allowance (880 ) (1,386 ) Valuation allowance, December 31, $ 3,663 $ 4,543 At December 31, 2023, the Company had net operating loss carryforwards for federal and state income tax purposes of approximately $18 million expiring at various dates from 2023 through 2037 and approximately $7 million with no expiration date. Under current tax law, the utilization of tax attributes will be restricted if an ownership change, as defined, were to occur. Section 382 of the Internal Revenue Code provides, in general, that if an “ownership change” occurs with respect to a corporation with net operating and other loss carryforwards, such carryforwards will be available to offset taxable income in each taxable year after the ownership change only up to the “Section 382 Limitation” for each year (generally, the product of the fair market value of the corporation’s stock at the time of the ownership change, with certain adjustments, and a specified long -term -exempt

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 11 — Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued and has determined that subject to the events below, there have been no events that have occurred that would require adjustments to the disclosures of the financial statements. In connection with the proposed Business Combination with Vaso Corporation, the Company filed a registration statement on Form S -4 -276422 On March 13, 2024, the Company notified the trustee of the Company’s Trust Account that it was exercising a Monthly Extension Option, extending the time available to the Company to consummate a Business Combination, from March 19, 2024 to April 19, 2024 (the “Third Extension”), pursuant to and in accordance with the terms of the Company’s Fifth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation” or the “Fourth Amended and Restated Certificate of Incorporation”) and the Company’s Third Amended and Restated Investment Management Trust Agreement (the “Trust Agreement”). The Third Extension is the third of up to six (6) one -month Pursuant to the terms of the Company’s Certificate of Incorporation and Trust Agreement, on March 13, 2024, with respect to the exercise of the Third Extension, the Company deposited $22,037.64 into the Company’s Trust Account in connection with the exercise of the First Extension. Such deposit with respect to the Third Extension was made using funds held outside of the Company’s Trust Account and available to the Company to fund working capital requirements. As of March 19, 2024 (and, for the avoidance of doubt, inclusive of the deposit of $22,037.64 into the Trust Account in connection with the exercise of the First Extension as described above), the Trust Account held approximately $6,145,817.

Revisions

Revisions	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Revisions [Line Items]
REVISIONS	NOTE B — REVISIONS We record commission revenue for certain products in our professional sales service segment based on GEHC’s reporting and payment of such commissions to us. In late August 2023, GEHC informed the Company that its calculations for such products were partially inaccurate and had remitted excess commissions. The Company has taken immediate steps to implement additional internal control procedures whereby GEHC will provide additional information sufficient to assess the accuracy of such commission payments going forward. We assessed the materiality of this misstatement on prior periods’ financial statements in accordance with SEC Staff Accounting Bulletin (“SAB”) Topic 1.M, Materiality, codified in Accounting Standards Codification (“ASC”) Topic 250, Accounting Changes and Error Corrections, (“ASC 250”) and concluded that the misstatements were not material to the prior annual or interim periods. Accordingly, in accordance with ASC 250 (SAB No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements), we have increased the accumulated deficit at January 1, 2022 by $229,000 to reflect $287,000 lower commission revenue and $58,000 lower commission expense, and corrected the accompanying Consolidated Balance Sheets as of December 31, 2022 and the Consolidated Statements of Operations and Comprehensive Income, Cash Flows, and Changes in Stockholders’ Equity for the year ended December 31, 2022, and the related notes to revise for those misstatements that impacted such periods. The following are selected line items from the Company’s Consolidated Financial Statements illustrating the effect of these corrections: Consolidated Balance Sheet As of December 31, 2022 (in thousands) As Reported Adjustment As Revised Accounts and other receivables $ 15,524 $ (1,010 ) $ 14,514 Accrued commissions $ 3,720 $ (202 ) $ 3,518 Accumulated deficit $ (39,029 ) $ (808 ) $ (39,837 ) Consolidated Statement of Operations and Year ended December 31, 2022 (in thousands, except per share data) As Reported Adjustment As Revised Revenues Professional sales services $ 37,344 $ (723 ) $ 36,621 Cost of revenues Cost of professional sales services $ 7,056 $ (144 ) $ 6,912 Gross Profit – professional sales services segment $ 30,288 $ (579 ) $ 29,709 Operating income $ 7,033 $ (579 ) $ 6,454 Net income $ 11,873 $ (579 ) $ 11,294 Comprehensive income $ 11,530 $ (579 ) $ 10,951 Income per common share – basic $ 0.07 $ (0.00 ) $ 0.07 – diluted $ 0.07 $ (0.00 ) $ 0.06 Consolidated Statement of Changes in Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity (in thousands) As Reported Adjustment As Revised As Reported Adjustment As Revised Balance at January 1, 2022 $ (50,902 ) $ (229 ) $ (51,131 ) $ 11,310 $ (229 ) $ 11,081 Net income $ 11,873 $ (579 ) $ 11,294 $ 11,873 $ (579 ) $ 11,294 Balance at December 31, 2022 $ (39,029 ) $ (808 ) $ (39,837 ) $ 22,875 $ (808 ) $ 22,067 Consolidated Statement of Cash Flows Year ended December 31, 2022 (in thousands) As Reported Adjustment As Revised Net income $ 11,873 $ (579 ) $ 11,294 Accounts and other receivables $ (243 ) $ 723 $ 480 Accrued commissions $ 1,094 $ (144 ) $ 950

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Segment Reporting [Line Items]
SEGMENT REPORTING	NOTE D — SEGMENT REPORTING The Company views its business in three segments — the IT segment, the professional sales service segment, and the equipment segment. The IT segment includes the operations of NetWolves and VasoHealthcare IT Corp. The professional sales service segment operates through the VasoHealthcare subsidiary and is currently engaged solely in the fulfillment of the Company’s responsibilities under our agreement with GEHC. The equipment segment is engaged in designing, manufacturing, marketing and supporting of proprietary medical devices and software, as well as managing the domestic business of EECP ® The chief operating decision maker is the Company’s Chief Executive Officer, who, in conjunction with upper management, evaluates segment performance based on operating income and Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization — defined as net (loss) income, plus net interest expense (income), tax expense, depreciation and amortization, and non -cash -based Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets — primarily cash balances — are reported in the Corporate entity below. There are no intersegment revenues. Summary financial information for the segments is set forth below: (in thousands) Year ended December 31, 2023 2022 Revenues from external customers IT $ 40,371 $ 40,100 Professional sales service 37,820 36,621 Equipment 2,833 2,573 Total revenues $ 81,024 $ 79,294 Gross Profit IT $ 17,659 $ 16,229 Professional sales service 30,799 29,709 Equipment 2,135 1,964 Total gross profit $ 50,593 $ 47,902 Operating income (loss) IT $ (466 ) $ (1,620 ) Professional sales service 7,195 9,520 Equipment (451 ) (180 ) Corporate (2,083 ) (1,266 ) Total operating income $ 4,195 $ 6,454 Depreciation and amortization IT $ 869 $ 1,692 Professional sales service 84 33 Equipment 46 198 Corporate — — Total depreciation and amortization $ 999 $ 1,923 Capital expenditures IT $ 357 $ 406 Professional sales service 87 125 Equipment 287 34 Corporate — 1 Total cash capital expenditures $ 731 $ 566 December 31, December 31, Identifiable Assets IT $ 22,425 $ 22,201 Professional sales service 18,955 20,674 Equipment 7,114 6,957 Corporate 27,263 21,813 Total assets $ 75,757 $ 71,645 For the years ended December 31, 2023 and 2022, GEHC accounted for 47% and 46% of revenue, respectively. Also, GEHC accounted for $9.3 million, or 75%, and $11.8 million, or 81%, of accounts and other receivables at December 31, 2023 and 2022, respectively. Our revenues were derived from the following geographic areas: (in thousands) Year ended December 31, 2023 2022 Domestic (United States) $ 78,843 $ 77,062 Non-domestic (foreign) 2,181 $ 2,232 $ 81,024 $ 79,294

Accounts and Other Receivables

Accounts and Other Receivables	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Accounts and Other Receivables [Line Items]
ACCOUNTS AND OTHER RECEIVABLES	NOTE E — ACCOUNTS AND OTHER RECEIVABLES The following table presents information regarding the Company’s accounts and other receivables as of December 31, 2023 and 2022: (in thousands) December 31, 2023 December 31, 2022 Trade receivables $ 22,085 $ 21,461 Allowance for credit losses and commission adjustments (9,708 ) (6,947 ) Accounts and other receivables, net $ 12,377 $ 14,514 Trade receivables include amounts due for shipped products and services rendered. Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change. Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from estimated future changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Inventories [Line Items]
INVENTORIES	NOTE F — INVENTORIES Inventories, net of reserves, consisted of the following: (in thousands) December 31, 2023 December 31, 2022 Raw materials $ 832 $ 751 Work in process 11 6 Finished goods 627 716 $ 1,470 $ 1,473 At December 31, 2023 and 2022, the Company maintained reserves for slow moving inventories of $164,000 and $163,000, respectively.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Property and Equipment [Line Items]
PROPERTY AND EQUIPMENT	NOTE G — PROPERTY AND EQUIPMENT Property and equipment is summarized as follows: (in thousands) December 31, 2023 December 31, 2022 Office, laboratory and other equipment $ 2,084 $ 1,928 Equipment furnished for customer use 8,233 7,981 Right of use assets – finance leases 1,116 1,119 Furniture and fixtures 99 99 11,532 11,127 Less: accumulated depreciation and amortization (10,358 ) (9,787 ) Property and equipment, net $ 1,174 $ 1,340 Accumulated amortization of right of use (“ROU”) assets under finance leases aggregated approximately $951,000 and $858,000 at December 31, 2023 and 2022, respectively. Depreciation expense amounted to approximately $635,000 and $1,372,000 for the years ended December 31, 2023 and 2022, respectively. Amortization of ROU assets under finance leases is included in depreciation expense.

Goodwill and Other Intangibles

Goodwill and Other Intangibles	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Goodwill and Other Intangibles [Line Items]
GOODWILL AND OTHER INTANGIBLES	NOTE H — GOODWILL AND OTHER INTANGIBLES Goodwill of $14,375,000 is attributable to the NetWolves reporting unit within the IT segment. The remaining $1,213,000 of goodwill is attributable to the FGE reporting unit within the Equipment segment. The changes in the carrying amount of goodwill are as follows: (in thousands) Year ended Year ended Beginning of period $ 15,614 $ 15,722 Foreign currency translation adjustment (26 ) (108 ) End of period $ 15,588 $ 15,614 The Company’s other intangible assets consist of capitalized customer -related (in thousands) December 31, 2023 December 31, 2022 Customer-related Costs $ 5,831 $ 5,831 Accumulated amortization (4,790 ) (4,557 ) 1,041 1,274 Patents and Technology Costs 1,894 1,894 Accumulated amortization (1,894 ) (1,894 ) — — Software Costs 2,618 2,362 Accumulated amortization (2,253 ) (2,125 ) 365 237 $ 1,406 $ 1,511 The Company owns, through our Chinese subsidiaries, thirty -five -line -year -year -related -related -line -line Amortization expense amounted to approximately $361,000 and $551,000 for the years ended December 31, 2023 and 2022, respectively. Amortization of intangibles for the next five years is: Years ending December 31, (in thousands) 2024 325 2025 254 2026 199 2027 169 2028 131 $ 1,078

Other Assets

Other Assets	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Other Assets [Line Items]
OTHER ASSETS	NOTE I — OTHER ASSETS Other assets consist of the following: (in thousands) December 31, 2023 December 31, 2022 Deferred commission expense – noncurrent $ 3,821 $ 3,864 Trade receivables – noncurrent 1,021 792 Other, net of allowance for loss on loan receivable of $412 at December 31, 2023 and 2022 60 70 $ 4,902 $ 4,726

Deferred Revenue

Deferred Revenue	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Deferred Revenue [Line Items]
DEFERRED REVENUE	NOTE J — DEFERRED REVENUE The changes in the Company’s deferred revenues are as follows: (in thousands) Year ended December 31, 2023 2022 Deferred revenue at beginning of period $ 30,803 $ 24,965 Net additions: Deferred extended service contracts 2 3 Deferred commission revenues 15,064 19,666 Recognized as revenue: Deferred extended service contracts (4 ) (4 ) Deferred commission revenues (13,665 ) (13,827 ) Deferred revenue at end of period 32,200 30,803 Less: current portion 15,883 15,139 Long-term deferred revenue at end of period $ 16,317 $ 15,664

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Accrued Expenses and Other Liabilities [Line Items]
ACCRUED EXPENSES AND OTHER LIABILITIES	NOTE K — ACCRUED EXPENSES AND OTHER LIABILITIES Accrued expenses and other liabilities consist of the following: (in thousands) December 31, 2023 December 31, 2022 Accrued compensation $ 2,482 $ 2,652 Accrued expenses – other 2,142 2,012 Order reduction liability 971 2,577 Other liabilities 1,770 1,650 $ 7,365 $ 8,891

Notes Payable and Revolving Cre

Notes Payable and Revolving Credit Agreement	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Notes Payable and Revolving Credit Agreement [Line Items]
NOTES PAYABLE AND REVOLVING CREDIT AGREEMENT	NOTE M — NOTES PAYABLE AND REVOLVING CREDIT AGREEMENT Notes payable consists of the following: (in thousands) December 31, 2023 December 31, 2022 Notes payable 15 24 Less: current portion (9 ) (9 ) $ 6 $ 15 Notes payable consists of a vehicle loan. The note is secured by the vehicle, bears interest at 1.9% per annum and matures in August 2025. On December 30, 2022, the Company executed a $3.0 million revolving credit agreement with a lending institution. Advances under the agreement bear interest at Wall Street Journal Prime Rate and are secured by substantially all of the assets of the Company. The agreement expired August 31, 2023 and was renewed through August 31, 2024. The agreement includes certain financial covenants, and the Company was in compliance with such covenants at December 31, 2023, at which time no amounts had been drawn.

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Leases [Line Items]
LEASES	NOTE N — LEASES The Company enters into finance leases, typically with terms of 3 to 5 7 Finance and operating lease liabilities consist of the following: (in thousands) December 31, 2023 December 31, 2022 Lease liabilities – current Finance leases $ 72 $ 122 Operating leases 928 745 $ 1,000 $ 867 Lease liabilities – net of current portion Finance leases $ 25 $ 96 Operating leases 1,020 823 $ 1,045 $ 919 A reconciliation of undiscounted cash flows to finance and operating lease liabilities recognized in the consolidated balance sheet at December 31, 2023 is set forth below: (in thousands) Years ending December 31, Finance Operating Total 2024 83 932 1,015 2025 25 697 722 2026 — 406 406 2027 — 124 124 Undiscounted lease payments 108 2,159 2,267 Amount representing interest (11 ) (211 ) (222 ) Discounted lease liabilities 97 1,948 2,045 Additional disclosures of lease data are set forth below: (in thousands) Year ended December 31, 2023 2022 Lease costs: Finance lease costs: Amortization of right-of-use assets $ 107 $ 154 Interest on lease liabilities 23 44 130 198 Operating lease costs 1,011 878 Short-term lease costs 52 52 Total lease cost 1,193 $ 1,128 Other information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 144 $ 44 Operating cash flows from operating leases 1,011 878 Financing cash flows from finance leases 119 222 1,274 $ 1,144 December 31, 2023 December 31, 2022 Weighted-average remaining lease term – finance leases (months) 16 23 Weighted-average remaining lease term – operating leases (months) 31 30 Weighted-average discount rate – finance leases 16.4 % 14.2 % Weighted-average discount rate – operating leases 8.4 % 9.1 % The Company used the rate implicit in the lease, where known, or its incremental borrowing rate as the rate used to discount the future lease payments.

Equity in the Eecp Business

Equity in the Eecp Business	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Equity in the Eecp Business [Line Items]
EQUITY IN THE EECP BUSINESS	NOTE O — EQUITY IN THE EECP BUSINESS On May 20, 2020, the Company closed on the sale of 51% of the capital stock of its then wholly -owned -Health -Tech -based -year The Company uses the equity method to account for its interest in EECP Global, as it has the ability to exercise significant influence over the entity, and reports its share of EECP Global operations in Other Income (Expense) on its consolidated statements of operations and comprehensive income. For the years ended December 31, 2023 and 2022, the Company’s share of EECP Global’s loss was approximately $206,000 and $154,000, respectively. At December 31, 2023 and 2022, the Company recorded Receivables due from related parties, net of approximately $901,000 and $403,000, respectively, on its consolidated balance sheets for amounts due from EECP Global for fees and cost reimbursements, net of receivables collected on its behalf due to EECP Global.

Option and Stock Issuance Plans

Option and Stock Issuance Plans	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Option and Stock Issuance Plans [Line Items]
OPTION AND STOCK ISSUANCE PLANS	NOTE Q — OPTION AND STOCK ISSUANCE PLANS 2013 Stock Option and Stock Issuance Plan On October 30, 2013, the Board of Directors (“Board”) approved the 2013 Stock Plan (the “2013 Plan”) for officers, directors, employees and consultants of the Company. The stock issuable under the 2013 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock. The maximum number of shares of common stock which may be issued under the 2013 Plan is 7,500,000 The 2013 Plan is comprised of two separate equity programs, the Options Grant Program, under which eligible persons may be granted options to purchase shares of common stock, and the Stock Issuance Program, under which eligible persons may be issued shares of common stock directly, either through the immediate purchase of such shares or as a bonus for services rendered to the Company. The 2013 Plan provides that the Board, or a committee of the Board, will administer it with full authority to determine the identity of the recipients of the options or shares and the number of options or shares. During the year ended December 31, 2023, no options or shares of common stock were granted or forfeited, and 759,120 2016 Stock Issuance Plan On June 15, 2016, the Board approved the 2016 Stock Plan (the “2016 Plan”) for officers, directors, and senior employees of the Corporation or any subsidiary of the Corporation. The stock issuable under the 2016 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock. The maximum number of shares of common stock that may be issued under the 2016 Plan is 7,500,000 The 2016 Plan consists of a Stock Issuance Program, under which eligible persons may, at the discretion of the Board, be issued shares of common stock directly, as a bonus for services rendered or to be rendered to the Corporation or any subsidiary of the Corporation. During the year ended December 31, 2023, 225,000 2019 Stock Issuance Plan In May 2019, the Board approved the 2019 Stock Plan (the “2019 Plan”) for officers, directors, and senior employees of the Corporation or any subsidiary of the Corporation. The stock issuable under the 2019 Plan shall be shares of the Company’s authorized but unissued or reacquired common stock. The maximum number of shares of common stock that may be issued under the 2019 Plan is 15,000,000 The 2019 Plan consists of a Stock Issuance Program, under which eligible persons may, at the discretion of the Board, be issued shares of common stock directly, as a bonus for services rendered or to be rendered to the Corporation or any subsidiary of the Corporation. During the year ended December 31, 2023, no shares were granted under the 2019 Plan. The following table summarizes non -vested Shares Available Unvested Weighted Balance at December 31, 2021 10,915,580 2,990,000 $ 0.02 Authorized — — $ — Granted (1,050,000 ) 1,050,000 $ 0.11 Vested — (1,300,000 ) $ 0.02 Forfeited 90,000 (90,000 ) $ 0.05 Expired — — $ — Balance at December 31, 2022 9,955,580 2,650,000 $ 0.06 Authorized — — $ — Granted (225,000 ) 225,000 $ 0.22 Vested — (1,491,418 ) $ 0.03 Forfeited 25,249 (25,249 ) $ 0.11 Expired (759,120 ) — $ — Balance at December 31, 2023 8,996,709 1,358,333 $ 0.11 There were 54,317,575 remaining authorized shares of common stock after reserves for all stock option plans.

401(k) Plans

401(k) Plans	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
401(k) Plans [Line Items]
401(k) PLANS	NOTE T - 401(k) PLANS The Company maintains a defined contribution plan to provide retirement benefits for its employees — the Vaso Corporation 401(k) Plan adopted in April 1997. As allowed under Section 401(k) of the Internal Revenue Code, the plan provides tax -deferred

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies, by Policy (Policies) [Line Items]
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC.
Emerging Growth Company	Emerging Growth Company The Company is an emerging growth company as defined in Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), which exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non -emerging This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short -term
Marketable Securities Held in the Trust Account	Marketable Securities Held in the Trust Account At December 31, 2023 and 2022, substantially all of the assets held in the Trust Account were held in cash and mutual fund that invests in U.S. Treasury securities respectively. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in the Trust Account are included in Interest and dividend income on cash and marketable securities held in the Trust Account in the accompanying statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. At December 31, 2023 and 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the Financial Accounting Standards Board (“FASB”) ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short -term
Income Taxes	Income Taxes The Company complies with the accounting and reporting requirements of ASC Topic 740, “Income Taxes” (“ASC 740”), which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2023 and 2022. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the years ended December 31, 2023 and 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. (see Note 10)
Common Stock Subject to Possible Redemption	Common Stock Subject to Possible Redemption The Company accounts for its Common Stock subject to possible redemption in accordance with the guidance in ASC 480, “Distinguishing Liabilities from Equity” (“ASC 480”). Shares of Common Stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable Common Stock (including Common Stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times Common Stock is classified as stockholders’ equity. The Company’s Common Stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at December 31, 2023, 550,941 shares of Common Stock subject to possible redemption are presented as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Common Stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable Common Stock are affected by charges against additional paid -in At December 31, 2023, the Common Stock subject to possible redemption reflected in the balance sheet is reconciled in the following table: Gross proceeds $ 100,000,000 Less: Proceeds allocated to Public Warrants (11,900,000 ) Common Stock issuance costs (5,322,219 ) Plus: Remeasurement of carrying value to redemption value 18,722,219 Common Stock subject to possible redemption as of December 31, 2021 101,500,000 Less: Redemption of Common Stock (57,810,572 ) Common Stock redemption payable (34,198,758 ) Plus: Remeasurement of carrying value to redemption value (net) 998,892 Common Stock subject to possible redemption as of December 31, 2022 10,489,562 Redemption of Common Stock (4,955,663 ) Plus: Remeasurement of carrying value to redemption value 515,846 Common Stock subject to possible redemption as of December 31, 2023 $ 6,049,745
Net (Loss) Income per Common Stock	Net (Loss) Income per Common Stock The Company has one class of shares. Public Warrants (see Note 3) and Private Placement Warrants (see Note 4) to purchase 12,850,000 shares of Common Stock at $11.50 per share were issued on October 19, 2021. As of December 31, 2023, no Public Warrants or Private Placement Warrants have been exercised. The 12,850,000 potential shares of Common Stock for outstanding Public Warrants and Private Placement Warrants to purchase the Common Stock were excluded from diluted earnings per share for the year ended December 31, 2023 because they are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net (loss) income per share of Common Stock is the same as basic net (loss) income per shares of Common Stock for the period. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net (loss) income per share for each class of stock. For the For the Basic and diluted net (loss) income per share: Numerator: Allocation of net (loss) income $ (2,574,642 ) $ 1,623,367 Denominator: Weighted average shares outstanding 3,336,745 12,278,562 Basic and diluted net (loss) income per share $ (0.77 ) $ 0.13
Accounting for Warrants	Accounting for Warrants The Company accounts for warrants as either equity -classified -classified classification. This assessment, which requires the use of professional judgment, was conducted at the time of warrant issuance and as of each subsequent period end date while the instruments are outstanding. Management has concluded that the Public Warrants qualify for equity accounting treatment and the Private Placement Warrants issued pursuant to the warrant agreement qualify for liability accounting treatment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020 -06 -20 -40 -06 -linked -06 The Company has reviewed other recent accounting pronouncements and concluded that they are either not applicable to the Company or no material effect is expected on the financial statements as a result of future adoption.
Vaso Corporation and Subsidaries [Member]
Accounting Policies, by Policy (Policies) [Line Items]
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions relate to estimates of commission adjustments due to order cancellations, collectability of accounts receivable, the realizability of deferred tax assets, stock -based
Concentration of Credit Risk	Concentrations of Credit Risk We market our equipment and IT software solutions principally to hospitals, diagnostic imaging centers and physician private practices. We perform credit evaluations of our customers’ financial condition and, as a result, believe that our receivable credit risk exposure is limited. For the years ended December 31, 2023 and 2022, no customer in our equipment or IT segment accounted for 10% or more of revenues or accounts receivable. In our professional sales service segment, 100% of our revenues and accounts receivable are with GEHC; however, we believe this risk is acceptable based on GEHC’s financial position and our long history of doing business with GEHC. The Company maintains cash balances in certain U.S. financial institutions which exceed the Federal Depository Insurance Corporation (“FDIC”) coverage of $250,000 by approximately $10,054,000. The Company has not experienced any losses on these accounts and believes it is not subject to any significant credit risk on these accounts. In addition, the FDIC does not insure the Company’s foreign bank balances, which aggregated approximately $467,000 and $1,234,000 at December 31, 2023 and 2022, respectively.
Fair Value of Financial Instruments	Financial Instruments The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows: Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model -derived Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The carrying amount of assets and liabilities including cash and cash equivalents, short -term -measured The following table presents information about the Company’s assets measured at fair value as of December 31, 2023 and 2022: Quoted Prices Significant Significant Balance as of Assets Cash equivalents invested in money market funds and treasury bills $ 10,522 $ — $ — $ 10,522 Bank deposits (included in short term investments) 424 424 $ 10,946 $ — $ — $ 10,946 Quoted Prices Significant Significant Balance as of Assets Cash equivalents invested in money market funds $ 7,934 $ — $ — $ 7,934 Bank deposits (included in short term investments) 433 433 $ 8,367 $ — $ — $ 8,367
Income Taxes	Income Taxes Deferred income taxes are recognized for temporary differences between financial statement and income tax bases of assets and liabilities and loss carry -forwards The Company also complies with the provisions of ASC Topic 740, “Income Taxes”, which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more -likely-than-not No
Net (Loss) Income per Common Stock	Net Income Per Common Share Basic income per common share is based on the weighted average number of common shares outstanding, including vested restricted shares, without consideration of potential common stock. Diluted earnings per common share is based on the weighted average number of common and potential dilutive common shares outstanding. Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares. A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows: (in thousands) Year ended December 31, 2023 2022 Basic weighted average shares outstanding 174,441 173,065 Dilutive effect of unvested restricted shares 1,100 1,591 Diluted weighted average shares outstanding 175,541 174,656 No
Recent Accounting Pronouncements	Recently Adopted Accounting Standards On January 1, 2023 the Company adopted ASU No. 2021 -08 -20 On January 1, 2023 the Company adopted ASU No. 2022 -04 -50 obligations are recorded in the balance sheet, and a rollforward of the obligations. As the Company does not engage in supplier finance programs, the adoption of this standard did not have a material impact on its Consolidated Financial Statements as of January 1, 2023.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Vaso Corporation, its wholly -owned
Revenue Recognition	Revenue Recognition In May 2014, the FASB issued ASU 2014 -09 -09 -step • Revenue relating to recurring managed network and voice services provided by NetWolves, for which the customer has unlimited access to such services throughout the contract term, are thus recognized as provided on a monthly basis (“over time”). Non -recurring -implementation -ready • Commission revenue is recognized when the underlying equipment has been delivered by GEHC and accepted at the customer site in accordance with the terms of the specific sales agreement (“point in time”). • In the United States, we recognized revenue from the sale of our medical equipment in the period in which we deliver the product to the customer (“point in time”). Revenue from the sale of our medical equipment to international markets is recognized upon shipment of the product to a common carrier, as are supplies, accessories and spare parts delivered in both domestic and international markets (“point in time”). Revenue from the provision of ARCS ® -billed
Disaggregation of Revenue	Disaggregation of Revenue The following tables present revenues disaggregated by our business operations and timing of revenue recognition: (in thousands) Year Ended December 31, 2023 Year Ended December 31, 2022 IT Professional Equipment Total IT Professional Equipment Total Network services $ 35,673 $ — $ — $ 35,673 $ 35,833 $ — $ — $ 35,833 Software sales and support 4,698 — — 4,698 4,267 — — 4,267 Commissions — 37,820 — 37,820 — 36,621 — 36,621 Medical equipment sales — — 2,708 2,708 — — 2,450 2,450 Medical equipment service — — 125 125 — — 123 123 $ 40,371 $ 37,820 $ 2,833 $ 81,024 $ 40,100 $ 36,621 $ 2,573 $ 79,294 Year Ended December 31, 2023 Year Ended December 31, 2022 IT Professional Equipment Total IT Professional Equipment Total Revenue recognized over $ 37,223 $ — $ 600 $ 37,823 $ 37,089 $ — $ 325 $ 37,414 Revenue recognized at a point in time 3,148 37,820 2,233 43,201 3,011 36,621 2,248 41,880 $ 40,371 $ 37,820 $ 2,833 $ 81,024 $ 40,100 $ 36,621 $ 2,573 $ 79,294
Transaction Price Allocated to Remaining Performance Obligations	Transaction Price Allocated to Remaining Performance Obligations As of December 31, 2023, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $95 million, of which we expect to recognize revenue as follows: (in thousands) Fiscal years of revenue recognition 2024 2025 2026 Thereafter Unfulfilled performance obligations $ 44,667 $ 19,861 $ 6,240 $ 23,918 As of December 31, 2022, the aggregate amount of transaction price allocated to performance obligations that were unsatisfied (or partially unsatisfied) for executed contracts approximated $91 million.
Contract Balances	Contract Balances Contract receivables include trade receivables, net and long -term -based -live -live -live In our VasoHealthcare business, we bill a portion of commissions on the orders we booked in advance of delivery of the underlying equipment. Such amounts aggregated approximately $32,194,000 and $30,794,000 at December 31, 2023 and 2022, respectively, and are classified in our consolidated balance sheets into current or long -term In our VasoMedical business, we bill amounts for post -delivery -term The following table summarizes the Company’s contract receivable and contract liability balances: (in thousands) 2023 2022 Contract receivables – January 1 15,306 15,474 Contract receivables – December 31 13,398 15,306 Increase (decrease) (1,909 ) (168 ) Contract liabilities – January 1 33,861 26,890 Contract liabilities – December 31 33,589 33,861 Increase (decrease) (272 ) 6,971 The decrease in contract receivables and liabilities in 2023 is due primarily to increased estimate of allowance for commission adjustments in our VasoHealthcare business. During the years ended December 31, 2023 and 2022, we recognized approximately $9.2 million and $9.1 million, respectively, of revenues that were included in our contract liability balance at the beginning of such periods.
Costs to Obtain or Fulfill a Contract	Costs to Obtain or Fulfill a Contract Topic 606 requires that incremental costs of obtaining a contract are recognized as an asset and amortized to expense in a pattern that matches the timing of the revenue recognition of the related contract. We have determined the only significant incremental costs incurred to obtain contracts with customers within the scope of Topic 606 are certain sales commissions paid to associates. In addition, the Company elected the practical expedient to recognize the incremental costs of obtaining a contract when incurred for contracts where the amortization period for the asset the Company would otherwise have recognized is one year or less. Under Topic 606, sales commissions applicable to service contracts exceeding one year have been capitalized and amortized ratably over the term of the contract. In our VHC IT business, commissions allocable to multi -year -year -contract -year -live At December 31, 2023 and 2022, our consolidated balance sheets include approximately $7,106,000 and $7,113,000, respectively, in capitalized sales commissions — primarily in our professional sales services segment — to be expensed in future periods, of which $3,285,000 and $3,249,000, respectively, is recorded in deferred commission expense and $3,821,000 and $3,864,000, respectively, representing the long -term
Significant Judgments when Applying Topic 606	Significant Judgments when Applying Topic 606 Contract transaction price is allocated to performance obligations using estimated stand -alone -alone -alone -alone -alone -alone Certain revenue we record in our professional sales service segment contains an estimate for variable consideration. Due to the tiered structure of our commission rate, which increases as annual targets are achieved, under Topic 606 we record revenue and deferred revenue at the rate we expect to be achieved by year end. We base our estimate of variable consideration on historical results of previous years’ achievement under the GEHC agreement. Such estimate is reviewed each quarter and adjusted as necessary. In addition, the Company records commissions for arranging financing at an estimated rate which is subject to later revision based on certain factors. The Company recognized increases (decreases) in revenue associated with revisions to variable consideration for previously completed performance obligations of $3,000 and $(5,000) for the years ended December 31, 2023 and 2022 respectively. The Company also records commission adjustments to contract liabilities in its professional sales service segment based on estimates of future order cancellations. Such cancellations also result in adjustments to the related capitalized cost to obtain or fulfill a contract.
Shipping and Handling Costs	Shipping and Handling CostsAll shipping and handling expenses are charged to cost of sales. Amounts billed to customers related to shipping and handling costs are included as a component of sales.
Research and Development	Research and Development Research and development costs attributable to development are expensed as incurred.
Share-Based Compensation	Share-Based Compensation The Company complies with ASC Topic 718, “Compensation — Stock Compensation” (“ASC 718”), which requires all companies to recognize the cost of services received in exchange for equity instruments to be recognized in the financial statements based on their grant date fair values. The Company applies an estimated forfeiture rate to the grant date fair value to determine the annual compensation cost of share -based -employees During the year ended December 31, 2023, the Company granted 225,000 restricted shares of common stock valued at $50,000 to employees. The shares vest over five years from the grant date. The total fair value of shares vested during the year ended December 31, 2023 was $27,000 for officers and $24,000 for employees. The weighted average grant date fair value of shares granted during the year ended December 31, 2023 was $0.22 per share, based on the closing price as of the grant date. During the year ended December 31, 2022, the Company granted 1,050,000 restricted shares of common stock valued at $115,000 to employees. The shares vest over three and five years from the grant date. The total fair value of shares vested during the year ended December 31, 2022 was $23,000 for officers and $4,000 for employees. The weighted average grant date fair value of shares granted during the year ended December 31, 2022 was $0.11 per share, based on the closing price as of the grant date. The Company did not grant any stock options during the years ended December 31, 2023 or 2022, nor were any options exercised during such periods. No options were outstanding at December 31, 2023 or 2022. Share -based -based -average
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents represent cash and short -term
Short term investments	Short term investments The Company’s short -term -month -to-maturity -for-sale -term
Accounts Receivable, net	Accounts Receivable, net The Company’s accounts receivable are due from customers to whom we sell our products and services, distributors engaged in the distribution of our products and from GEHC. Credit is extended based on evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are generally due 30 to 90 days from shipment and services provided and are stated at amounts due from customers net of allowances for doubtful accounts, returns, term discounts and other allowances. Accounts that are outstanding longer than the contractual payment terms are considered past due. Estimates are used in determining the allowance for doubtful accounts based on the Company’s historical collections experience, current trends, credit policy and a percentage of its accounts receivable by aging category. In determining these percentages, the Company reviews historical write -offs The changes in the Company’s allowance for doubtful accounts and commission adjustments are as follows: (in thousands) Year ended December 31, 2023 2022 Beginning Balance $ 6,947 $ 5,804 Provision for losses on accounts receivable 66 63 Direct write-offs, net of recoveries (60 ) (159 ) Commission adjustments 2,755 1,239 Ending Balance $ 9,708 $ 6,947
Inventories	Inventories The Company values inventories in the equipment segment at the lower of cost or net realizable value, with cost being determined on a first -in -out In our IT Segment, we purchase computer hardware and software for specific customer requirements and value such inventories using the specific identification method.
Property and Equipment	Property and Equipment Property and equipment, including assets under finance leases, are stated at cost less accumulated depreciation and amortization. Major improvements are capitalized and minor replacements, maintenance and repairs are charged to expense as incurred. Upon retirement or disposal of assets, the cost and related accumulated depreciation are removed from the consolidated balance sheets. Depreciation is expensed over the estimated useful lives of the assets, which range from two eight -line
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company reviews the recoverability of all long -lived -lived No
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill represents the excess of cost over the fair value of net assets of businesses acquired. The Company accounts for goodwill under the guidance of the ASC Topic 350, “Intangibles: Goodwill and Other”. Goodwill acquired in a purchase business combination and determined to have an indefinite useful life is not amortized, but instead tested for impairment, at least annually, in accordance with this guidance. The recoverability of goodwill is subject to an annual impairment test or whenever an event occurs or circumstances change that would more likely than not result in an impairment. The impairment test is based on the estimated fair value of the underlying businesses and performed in the fourth quarter of each year. We perform either a quantitative or qualitative assessment to assess if the fair value of the respective reporting unit exceeds its carrying value. The qualitative goodwill impairment assessment requires evaluating factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. As part of our goodwill qualitative assessment process for our two applicable reporting units, when utilized, we evaluate various factors that are specific to the reporting unit as well as industry and macroeconomic factors in order to determine whether it is reasonably likely to have a material impact on the fair value of our reporting units. Examples of the factors that are considered include the results of the most recent impairment test, current forecasts, and changes in the strategic outlook or organizational structure of the reporting units. The financial forecasts of the reporting units are compared to the forecasts used in the prior year analysis to determine if management expectations for the business have changed. When performing the quantitative assessment to calculate the fair value of a reporting unit, we consider both comparative market multiples as well as estimated discounted cash flows for the reporting unit. The significant estimates and assumptions include, but are not limited to, revenue growth rates, operating margins, and future economic and market conditions. The discount rates are based upon industry weighted average cost of capital ranges. As a supplement, we conduct additional sensitivity analysis to assess the risk for potential impairment based upon changes in the key assumptions such as the discount rate, expected long -term Based upon the completion of our annual test as of December 31, 2023 and 2022, we determined that there was no impairment of goodwill and that the applicable reporting units’ estimated fair values were substantially in excess of their carrying amounts. Intangible assets consist of the value of customer contracts and relationships, patent and technology costs, and software. The cost of significant customer -related -line five ten No
Deferred revenue	Deferred Revenue Amounts billable under the agreement with GEHC in advance of delivery of the underlying equipment are recorded initially as deferred revenue, and commission revenue is subsequently recognized as customer acceptance of such equipment is reported to us by GEHC. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized. In our equipment segment, we record revenue on extended service contracts ratably over the term of the related service contracts.
Foreign Currency Translation Gain (Loss) and Comprehensive Income	Foreign Currency Translation Gain (Loss) and Comprehensive Income In the country in which the Company operates, and the functional currency is other than the U.S. dollar, assets and liabilities are translated using published exchange rates in effect at the consolidated balance sheet date. Equity accounts are translated at historical rates except for the changes in accumulated deficit during the year as the result of the income statement translation process. Revenues and expenses and cash flows are translated using a weighted average exchange rate for the period. Resulting translation adjustments are recorded as a component of accumulated other comprehensive income (loss) on the accompanying consolidated balance sheets. For the years ended December 31, 2023 and 2022, other comprehensive income includes losses of $71,000 and $343,000, respectively, which were entirely from foreign currency translation loss.
Recently Issued Accounting Standards To Be Adopted	Recently Issued Accounting Standards To Be Adopted The Company continually assesses any new accounting pronouncements to determine their applicability to the Company. Where it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequence of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change. New pronouncements assessed by the Company recently are discussed below: In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023 -09 In November 2023, the FASB issued ASU 2023 -07

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Summary of Significant Accounting Policies (Tables) [Line Items]
Schedule of the Common Stock Subject to Possible Redemption Reflected in the Balance Sheet Is Reconciled	At December 31, 2023, the Common Stock subject to possible redemption reflected in the balance sheet is reconciled in the following table: Gross proceeds $ 100,000,000 Less: Proceeds allocated to Public Warrants (11,900,000 ) Common Stock issuance costs (5,322,219 ) Plus: Remeasurement of carrying value to redemption value 18,722,219 Common Stock subject to possible redemption as of December 31, 2021 101,500,000 Less: Redemption of Common Stock (57,810,572 ) Common Stock redemption payable (34,198,758 ) Plus: Remeasurement of carrying value to redemption value (net) 998,892 Common Stock subject to possible redemption as of December 31, 2022 10,489,562 Redemption of Common Stock (4,955,663 ) Plus: Remeasurement of carrying value to redemption value 515,846 Common Stock subject to possible redemption as of December 31, 2023 $ 6,049,745
Schedule of Basic and Diluted Net (Loss) Income Per Share	The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net (loss) income per share for each class of stock. For the For the Basic and diluted net (loss) income per share: Numerator: Allocation of net (loss) income $ (2,574,642 ) $ 1,623,367 Denominator: Weighted average shares outstanding 3,336,745 12,278,562 Basic and diluted net (loss) income per share $ (0.77 ) $ 0.13
Vaso Corporation and Subsidaries [Member]
Summary of Significant Accounting Policies (Tables) [Line Items]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition	The following tables present revenues disaggregated by our business operations and timing of revenue recognition: (in thousands) Year Ended December 31, 2023 Year Ended December 31, 2022 IT Professional Equipment Total IT Professional Equipment Total Network services $ 35,673 $ — $ — $ 35,673 $ 35,833 $ — $ — $ 35,833 Software sales and support 4,698 — — 4,698 4,267 — — 4,267 Commissions — 37,820 — 37,820 — 36,621 — 36,621 Medical equipment sales — — 2,708 2,708 — — 2,450 2,450 Medical equipment service — — 125 125 — — 123 123 $ 40,371 $ 37,820 $ 2,833 $ 81,024 $ 40,100 $ 36,621 $ 2,573 $ 79,294 Year Ended December 31, 2023 Year Ended December 31, 2022 IT Professional Equipment Total IT Professional Equipment Total Revenue recognized over $ 37,223 $ — $ 600 $ 37,823 $ 37,089 $ — $ 325 $ 37,414 Revenue recognized at a point in time 3,148 37,820 2,233 43,201 3,011 36,621 2,248 41,880 $ 40,371 $ 37,820 $ 2,833 $ 81,024 $ 40,100 $ 36,621 $ 2,573 $ 79,294
Schedule of Aggregate Amount of Transaction Price Allocated to Performance Obligations	As of December 31, 2023, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $95 million, of which we expect to recognize revenue as follows: (in thousands) Fiscal years of revenue recognition 2024 2025 2026 Thereafter Unfulfilled performance obligations $ 44,667 $ 19,861 $ 6,240 $ 23,918
Schedule of Contract Receivable and Contract Liability Balances	The following table summarizes the Company’s contract receivable and contract liability balances: (in thousands) 2023 2022 Contract receivables – January 1 15,306 15,474 Contract receivables – December 31 13,398 15,306 Increase (decrease) (1,909 ) (168 ) Contract liabilities – January 1 33,861 26,890 Contract liabilities – December 31 33,589 33,861 Increase (decrease) (272 ) 6,971
Schedule of Company’s Assets Measured at Fair Value	The following table presents information about the Company’s assets measured at fair value as of December 31, 2023 and 2022: Quoted Prices Significant Significant Balance as of Assets Cash equivalents invested in money market funds and treasury bills $ 10,522 $ — $ — $ 10,522 Bank deposits (included in short term investments) 424 424 $ 10,946 $ — $ — $ 10,946 Quoted Prices Significant Significant Balance as of Assets Cash equivalents invested in money market funds $ 7,934 $ — $ — $ 7,934 Bank deposits (included in short term investments) 433 433 $ 8,367 $ — $ — $ 8,367
Schedule of Company’s Allowance for Doubtful Accounts and Commission Adjustments	The changes in the Company’s allowance for doubtful accounts and commission adjustments are as follows: (in thousands) Year ended December 31, 2023 2022 Beginning Balance $ 6,947 $ 5,804 Provision for losses on accounts receivable 66 63 Direct write-offs, net of recoveries (60 ) (159 ) Commission adjustments 2,755 1,239 Ending Balance $ 9,708 $ 6,947
Schedule of Basic to Diluted Shares Used in the Earnings Per Share	Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares. A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows: (in thousands) Year ended December 31, 2023 2022 Basic weighted average shares outstanding 174,441 173,065 Dilutive effect of unvested restricted shares 1,100 1,591 Diluted weighted average shares outstanding 175,541 174,656

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2023
Fair Value Measurements [Abstract]
Schedule of Liabilities that are Measured at Fair Value on a Recurring Basis	The following tables present information about the Company’s liabilities that are measured at fair value on a recurring basis at December 31, 2023 and 2022 and indicate the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: December 31, 2023 Level Quoted Significant Significant Assets: Cash and marketable securities held in Trust Account 1 $ 6,049,745 $ — $ — Warrant Liability-Private Placement Warrants 3 $ — $ — $ 107,713 December 31, 2022 Level Quoted (Level 1) Significant Inputs (Level 2) Significant Inputs (Level 3) Assets: Marketable Securities 1 $ 44,688,320 $ — $ — Warrant Liability-Private Placement Warrants 3 $ — $ — $ 356,666
Schedule of Level 3 Fair Value Measurements	The following table provides quantitative information regarding Level 3 fair value measurements at December 31, 2023 and 2022: December 31, December 31, Stock Price $ 10.89 $ 10.22 Exercise Price $ 11.50 $ 11.50 Term (years) 0.96 2.91 Volatility 1.15 % 0.20 % Risk Free Rate 4.77 % 4.24 % Dividend Yield 0.00 % 0.00 %
Schedule of Changes in the Fair Value of Level 3 Warrant Labilities	The following table presents the changes in the fair value of Level 3 warrant labilities: Private Fair value as of October 19, 2021 (IPO) $ 9,986,666 Change in fair value (7,632,666 ) Fair value as of December 31, 2021 2,354,000 Change in fair value (1,997,334 ) Fair value as of December 31, 2022 356,666 Change in fair value (248,953 ) Fair value as of December 31, 2023 $ 107,713

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Taxes (Tables) [Line Items]
Schedule of Income Tax Provision	The total Income tax provision is comprised of the following for the years ended December 31, 2023 and 2022: December 31, December 31, Federal Current $ 72,980 $ 216,203 Deferred (688,629 ) (246,333 ) State and local Current — — Deferred — — Change in valuation allowance 688,629 246,333 Income tax provision $ 72,980 $ 216,203
Schedule of Deferred Tax Assets	The net deferred tax assets in the accompanying balance sheets included the following components: December 31, December 31, Deferred tax assets Start-up costs $ 688,629 $ 308,347 Net operating loss carryforward — — Total deferred tax asset 688,629 308,347 Valuation allowance (688,629 ) (308,347 ) Deferred tax asset net of allowance $ — $ —
Schedule of Effective Tax Rate	A reconciliation of the statutory federal income tax rate to the Company’s effective tax rate (approximate) is as follows: December 31, December 31, Statutory federal income tax rate 21.00 % 21.00 % State taxes, net of federal tax benefit 0.00 % 0.00 % Change in fair value of warrants 9.95 % (22.80 )% Warrant issuance costs 0.00 % 0.00 % Valuation allowance (27.53 )% 13.29 % Income tax provision expense (3.42 )% 11.49 %
Vaso Corporation and Subsidaries [Member]
Income Taxes (Tables) [Line Items]
Schedule of Income Tax Provision	The following is a geographical breakdown of income before the provision for income taxes: (in thousands) Year ended December 31, 2023 2022 Domestic $ 5,085 $ 6,244 Foreign (180 ) 307 Income before provision for income taxes $ 4,905 $ 6,551
Schedule of Deferred Tax Assets	The components of our deferred tax assets and liabilities are summarized as follows: (in thousands) December 31, 2023 December 31, 2022 Deferred Tax Assets: Net operating loss carryforwards $ 6,796 $ 8,367 Amortization 590 328 Stock-based compensation 4 7 Allowance for doubtful accounts 100 99 Reserve for slow moving inventory 46 46 Tax credits 324 416 Expense accruals 855 908 Capitalized R&D 13 — Deferred revenue 2,819 1,835 Total gross deferred taxes 11,547 12,006 Valuation allowance (3,663 ) (4,543 ) Net deferred tax assets 7,884 7,463 Deferred Tax Liabilities: Deferred commissions (701 ) (464 ) Goodwill (2,221 ) (1,962 ) Depreciation (7 ) (30 ) Total deferred tax liabilities (2,929 ) (2,456 ) Total deferred tax assets (liabilities) 4,955 5,007 Recorded as: Non-current deferred tax assets 4,955 5,007 Non-current deferred tax liabilities — — Total deferred tax assets (liabilities) $ 4,955 $ 5,007
Schedule of Effective Tax Rate	The following is a reconciliation of the effective income tax rate to the federal statutory rate: For the year ended December 31, 2023 December 31, 2022 % % Federal statutory rate 21.00 21.00 State income taxes 6.19 6.11 Change in valuation allowance relating to operations (17.96 ) (92.63 ) Foreign tax rate differential (2.71 ) (0.81 ) R&D credit 1.87 0.58 Nondeductible expenses 0.71 0.22 Other (7.06 ) (6.87 ) 2.04 (72.40 )
Schedule of Provision for Income Taxes	The provision for income taxes consisted of the following: (in thousands) Year ended December 31, 2023 2022 Current provision (benefit) Federal $ — $ — State 50 36 Foreign (1 ) 9 Total current provision (benefit) 49 45 Deferred provision (benefit) Federal 40 (3,724 ) State 11 (1,064 ) Foreign — — Total deferred provision (benefit) 51 (4,788 ) Total income tax provision (benefit) $ 100 $ (4,743 ) Effective income tax rate 2.04 % (72.40 )%
Schedule of the Valuation Allowance	The activity in the valuation allowance is set forth below: (in thousands) 2023 2022 Valuation allowance, January 1, $ 4,543 $ 10,769 Partial release of allowance — (4,840 ) Change in valuation allowance (880 ) (1,386 ) Valuation allowance, December 31, $ 3,663 $ 4,543

Revisions (Tables)

Revisions (Tables) - Vaso Corporation and Subsidaries [Member]	12 Months Ended
	Dec. 31, 2023
Revisions (Tables) [Line Items]
Schedule of Consolidated Financial Statements	The following are selected line items from the Company’s Consolidated Financial Statements illustrating the effect of these corrections: Consolidated Balance Sheet As of December 31, 2022 (in thousands) As Reported Adjustment As Revised Accounts and other receivables $ 15,524 $ (1,010 ) $ 14,514 Accrued commissions $ 3,720 $ (202 ) $ 3,518 Accumulated deficit $ (39,029 ) $ (808 ) $ (39,837 )
Schedule of Consolidated Statement of Operations and Comprehensive Income	Consolidated Statement of Operations and Year ended December 31, 2022 (in thousands, except per share data) As Reported Adjustment As Revised Revenues Professional sales services $ 37,344 $ (723 ) $ 36,621 Cost of revenues Cost of professional sales services $ 7,056 $ (144 ) $ 6,912 Gross Profit – professional sales services segment $ 30,288 $ (579 ) $ 29,709 Operating income $ 7,033 $ (579 ) $ 6,454 Net income $ 11,873 $ (579 ) $ 11,294 Comprehensive income $ 11,530 $ (579 ) $ 10,951 Income per common share – basic $ 0.07 $ (0.00 ) $ 0.07 – diluted $ 0.07 $ (0.00 ) $ 0.06
Schedule of Consolidated Statement of Changes in Stockholders’ Equity	Consolidated Statement of Changes in Stockholders’ Equity Accumulated Deficit Total Stockholders’ Equity (in thousands) As Reported Adjustment As Revised As Reported Adjustment As Revised Balance at January 1, 2022 $ (50,902 ) $ (229 ) $ (51,131 ) $ 11,310 $ (229 ) $ 11,081 Net income $ 11,873 $ (579 ) $ 11,294 $ 11,873 $ (579 ) $ 11,294 Balance at December 31, 2022 $ (39,029 ) $ (808 ) $ (39,837 ) $ 22,875 $ (808 ) $ 22,067
Schedule of Consolidated Statement of Cash Flows	Consolidated Statement of Cash Flows Year ended December 31, 2022 (in thousands) As Reported Adjustment As Revised Net income $ 11,873 $ (579 ) $ 11,294 Accounts and other receivables $ (243 ) $ 723 $ 480 Accrued commissions $ 1,094 $ (144 ) $ 950

Segment Reporting (Tables)

Segment Reporting (Tables) - Vaso Corporation and Subsidaries [Member]	12 Months Ended
	Dec. 31, 2023
Segment Reporting (Tables) [Line Items]
Schedule of Financial Information	There are no intersegment revenues. Summary financial information for the segments is set forth below: (in thousands) Year ended December 31, 2023 2022 Revenues from external customers IT $ 40,371 $ 40,100 Professional sales service 37,820 36,621 Equipment 2,833 2,573 Total revenues $ 81,024 $ 79,294 Gross Profit IT $ 17,659 $ 16,229 Professional sales service 30,799 29,709 Equipment 2,135 1,964 Total gross profit $ 50,593 $ 47,902 Operating income (loss) IT $ (466 ) $ (1,620 ) Professional sales service 7,195 9,520 Equipment (451 ) (180 ) Corporate (2,083 ) (1,266 ) Total operating income $ 4,195 $ 6,454 Depreciation and amortization IT $ 869 $ 1,692 Professional sales service 84 33 Equipment 46 198 Corporate — — Total depreciation and amortization $ 999 $ 1,923 Capital expenditures IT $ 357 $ 406 Professional sales service 87 125 Equipment 287 34 Corporate — 1 Total cash capital expenditures $ 731 $ 566 December 31, December 31, Identifiable Assets IT $ 22,425 $ 22,201 Professional sales service 18,955 20,674 Equipment 7,114 6,957 Corporate 27,263 21,813 Total assets $ 75,757 $ 71,645
Schedule of Geographic Areas	Our revenues were derived from the following geographic areas: (in thousands) Year ended December 31, 2023 2022 Domestic (United States) $ 78,843 $ 77,062 Non-domestic (foreign) 2,181 $ 2,232 $ 81,024 $ 79,294

Accounts and Other Receivables

Accounts and Other Receivables (Tables)	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Accounts and Other Receivables (Tables) [Line Items]
Schedule of Accounts and Other Receivables	The following table presents information regarding the Company’s accounts and other receivables as of December 31, 2023 and 2022: (in thousands) December 31, 2023 December 31, 2022 Trade receivables $ 22,085 $ 21,461 Allowance for credit losses and commission adjustments (9,708 ) (6,947 ) Accounts and other receivables, net $ 12,377 $ 14,514

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Inventories (Tables) [Line Items]
Schedule of Inventories, Net of Reserves	Inventories, net of reserves, consisted of the following: (in thousands) December 31, 2023 December 31, 2022 Raw materials $ 832 $ 751 Work in process 11 6 Finished goods 627 716 $ 1,470 $ 1,473

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Property and Equipment (Tables) [Line Items]
Schedule of Property and Equipment	Property and equipment is summarized as follows: (in thousands) December 31, 2023 December 31, 2022 Office, laboratory and other equipment $ 2,084 $ 1,928 Equipment furnished for customer use 8,233 7,981 Right of use assets – finance leases 1,116 1,119 Furniture and fixtures 99 99 11,532 11,127 Less: accumulated depreciation and amortization (10,358 ) (9,787 ) Property and equipment, net $ 1,174 $ 1,340

Goodwill and Other Intangibles

Goodwill and Other Intangibles (Tables) - Vaso Corporation and Subsidaries [Member]	12 Months Ended
	Dec. 31, 2023
Goodwill and Other Intangibles (Tables) [Line Items]
Schedule of Change in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill are as follows: (in thousands) Year ended Year ended Beginning of period $ 15,614 $ 15,722 Foreign currency translation adjustment (26 ) (108 ) End of period $ 15,588 $ 15,614
Schedule of Other Intangible Assets	The Company’s other intangible assets consist of capitalized customer -related (in thousands) December 31, 2023 December 31, 2022 Customer-related Costs $ 5,831 $ 5,831 Accumulated amortization (4,790 ) (4,557 ) 1,041 1,274 Patents and Technology Costs 1,894 1,894 Accumulated amortization (1,894 ) (1,894 ) — — Software Costs 2,618 2,362 Accumulated amortization (2,253 ) (2,125 ) 365 237 $ 1,406 $ 1,511
Schedule of Amortization of Intangibles	Amortization expense amounted to approximately $361,000 and $551,000 for the years ended December 31, 2023 and 2022, respectively. Amortization of intangibles for the next five years is: Years ending December 31, (in thousands) 2024 325 2025 254 2026 199 2027 169 2028 131 $ 1,078

Other Assets (Tables)

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Other Assets (Tables) [Line Items]
Schedule of Other Assets	Other assets consist of the following: (in thousands) December 31, 2023 December 31, 2022 Deferred commission expense – noncurrent $ 3,821 $ 3,864 Trade receivables – noncurrent 1,021 792 Other, net of allowance for loss on loan receivable of $412 at December 31, 2023 and 2022 60 70 $ 4,902 $ 4,726

Deferred Revenue (Tables)

Deferred Revenue (Tables)	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Deferred Revenue (Tables) [Line Items]
Schedule of Deferred Revenues	The changes in the Company’s deferred revenues are as follows: (in thousands) Year ended December 31, 2023 2022 Deferred revenue at beginning of period $ 30,803 $ 24,965 Net additions: Deferred extended service contracts 2 3 Deferred commission revenues 15,064 19,666 Recognized as revenue: Deferred extended service contracts (4 ) (4 ) Deferred commission revenues (13,665 ) (13,827 ) Deferred revenue at end of period 32,200 30,803 Less: current portion 15,883 15,139 Long-term deferred revenue at end of period $ 16,317 $ 15,664

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Accrued Expenses and Other Liabilities (Tables) [Line Items]
Schedule of Accrued Expenses and Other Liabilities	Accrued expenses and other liabilities consist of the following: (in thousands) December 31, 2023 December 31, 2022 Accrued compensation $ 2,482 $ 2,652 Accrued expenses – other 2,142 2,012 Order reduction liability 971 2,577 Other liabilities 1,770 1,650 $ 7,365 $ 8,891

Notes Payable and Revolving C_2

Notes Payable and Revolving Credit Agreement (Tables)	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Notes Payable and Revolving Credit Agreement (Tables) [Line Items]
Schedule of Notes Payable	Notes payable consists of the following: (in thousands) December 31, 2023 December 31, 2022 Notes payable 15 24 Less: current portion (9 ) (9 ) $ 6 $ 15

Leases (Tables)

Leases (Tables) - Vaso Corporation and Subsidaries [Member]	12 Months Ended
	Dec. 31, 2023
Leases (Tables) [Line Items]
Schedule of Finance and Operating Lease Liabilities	Finance and operating lease liabilities consist of the following: (in thousands) December 31, 2023 December 31, 2022 Lease liabilities – current Finance leases $ 72 $ 122 Operating leases 928 745 $ 1,000 $ 867 Lease liabilities – net of current portion Finance leases $ 25 $ 96 Operating leases 1,020 823 $ 1,045 $ 919
Schedule of Undiscounted Cash Flows to Finance and Operating Lease Liabilities	A reconciliation of undiscounted cash flows to finance and operating lease liabilities recognized in the consolidated balance sheet at December 31, 2023 is set forth below: (in thousands) Years ending December 31, Finance Operating Total 2024 83 932 1,015 2025 25 697 722 2026 — 406 406 2027 — 124 124 Undiscounted lease payments 108 2,159 2,267 Amount representing interest (11 ) (211 ) (222 ) Discounted lease liabilities 97 1,948 2,045
Schedule of Additional Disclosures of Lease Data	Additional disclosures of lease data are set forth below: (in thousands) Year ended December 31, 2023 2022 Lease costs: Finance lease costs: Amortization of right-of-use assets $ 107 $ 154 Interest on lease liabilities 23 44 130 198 Operating lease costs 1,011 878 Short-term lease costs 52 52 Total lease cost 1,193 $ 1,128 Other information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 144 $ 44 Operating cash flows from operating leases 1,011 878 Financing cash flows from finance leases 119 222 1,274 $ 1,144 December 31, 2023 December 31, 2022 Weighted-average remaining lease term – finance leases (months) 16 23 Weighted-average remaining lease term – operating leases (months) 31 30 Weighted-average discount rate – finance leases 16.4 % 14.2 % Weighted-average discount rate – operating leases 8.4 % 9.1 %

Option and Stock Issuance Pla_2

Option and Stock Issuance Plans (Tables)	12 Months Ended
	Dec. 31, 2023
Vaso Corporation and Subsidaries [Member]
Option and Stock Issuance Plans (Tables) [Line Items]
Schedule of Non Vested Restricted Share	The following table summarizes non -vested Shares Available Unvested Weighted Balance at December 31, 2021 10,915,580 2,990,000 $ 0.02 Authorized — — $ — Granted (1,050,000 ) 1,050,000 $ 0.11 Vested — (1,300,000 ) $ 0.02 Forfeited 90,000 (90,000 ) $ 0.05 Expired — — $ — Balance at December 31, 2022 9,955,580 2,650,000 $ 0.06 Authorized — — $ — Granted (225,000 ) 225,000 $ 0.22 Vested — (1,491,418 ) $ 0.03 Forfeited 25,249 (25,249 ) $ 0.11 Expired (759,120 ) — $ — Balance at December 31, 2023 8,996,709 1,358,333 $ 0.11

Description of Organization a_2

Description of Organization and Business Operations (Details) - USD ($)					12 Months Ended
	Oct. 19, 2021	May 20, 2020	Apr. 01, 2020	Jan. 31, 2015	Dec. 31, 2023	Mar. 13, 2024	Dec. 31, 2022	Dec. 31, 2021
Description of Organization and Business Operations [Line items]
Par value (in Dollars per share)					$ 0.0001		$ 0.0001
Deferred underwriting fee payable					$ 3,500,000		$ 3,500,000
Net proceed in sale of stock					$ 101,500,000
Net proceeds of sale (in Dollars per share)					$ 10.15
Maturity date					185 days
Least of assets held in trust account					80%
Aggregate common stock percentage					15%
Public shares					100%
Business combination consummation date					Jul. 19, 2024
Business combination consummation month					33 months
Business days thereafter					10 days
Interest to pay dissolution expenses					$ 100,000
Net tangible assets					5,000,001
Deposits					$ 100,000
Deposits asset price per share (in Dollars per share)					$ 0.04
Shares held in trust account price per share (in Dollars per share)					$ 10.15
Shares of common stock (in Shares)					87,380
Redeemed price per shares (in Dollars per share)					$ 10.9
Aggregate payment amount					$ 952,940
Cash					48,395
Trust account Iesser					6,049,745
Underwriting Agreement [Member]
Description of Organization and Business Operations [Line items]
Deferred underwriting fee payable					3,500,000
Common Stock [Member]
Description of Organization and Business Operations [Line items]
Par value (in Dollars per share)	$ 0.0001
Private Placement Warrants [Member]
Description of Organization and Business Operations [Line items]
Outstanding warrants					$ 107,713		$ 356,666	$ 2,354,000
IPO [Member]
Description of Organization and Business Operations [Line items]
Initial public offering (in Shares)					10,000,000
Number of shares issued per unit (in Shares)	1				1
Number of shares issued per unit (in Shares)	1				1
Shares issued, price per share (in Dollars per share)					$ 10
Initial public offering amount					$ 6,101,730
Initial public offering consisting					2,000,000
Deferred underwriting fee payable					3,500,000
Other costs					$ 601,730
IPO [Member] | Common Stock [Member]
Description of Organization and Business Operations [Line items]
Initial public offering (in Shares)	10,000,000
Shares issued, price per share (in Dollars per share)	$ 10
Gross proceeds	$ 100,000,000
IPO [Member] | Private Placement Warrants [Member]
Description of Organization and Business Operations [Line items]
Outstanding warrants	$ 9,986,666
Private Placement [Member]
Description of Organization and Business Operations [Line items]
Sale of stock price per share (in Dollars per share)	$ 0.75
Private Placement [Member] | Private Placement Warrants [Member]
Description of Organization and Business Operations [Line items]
Sale of stock (in Shares)	7,133,333
Vaso Corporation and Subsidaries [Member]
Description of Organization and Business Operations [Line items]
Par value (in Dollars per share)					$ 0.001		$ 0.001
Company owned rate				49.90%
Sale of the capital stock		51%
Initial term			3 years
Business combination value					$ 176,000,000
Pro forma equity value per share (in Dollars per share)					$ 10
Stockholders received amount					$ 17,600,000
Current shareholders amount					$ 500,000
Shares of common stock (in Shares)					750,000
Outstanding warrants					$ 8,250,000
Exercise price per share (in Dollars per share)					$ 11.5
Asset, Held-in-Trust [Member]
Description of Organization and Business Operations [Line items]
Amount on deposit in trust account					$ 429,125
Forecast [Member]
Description of Organization and Business Operations [Line items]
Deposits						$ 22,037.64
Business Combination [Member]
Description of Organization and Business Operations [Line items]
Business combination outstanding percentage					50%
Business Combination [Member] | Vaso Corporation and Subsidaries [Member]
Description of Organization and Business Operations [Line items]
Business combination outstanding percentage					44%
Public Stockholders [Member]
Description of Organization and Business Operations [Line items]
Public Share (in Dollars per share)					$ 10.15
Sponsor [Member] | Private Placement [Member] | Private Placement Warrants [Member]
Description of Organization and Business Operations [Line items]
Gross proceeds					$ 5,350,000
Sale of stock (in Shares)					7,133,333
Sale of stock price per share (in Dollars per share)					$ 0.75

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Oct. 19, 2021
Summary of Significant Accounting Policies [Line Items]
Cash equivalents at carrying value	$ 0	$ 0
Cash, FDIC insured amount	250,000
Unrecognized tax benefits	0	0
Unrecognized tax benefits, Income tax penalties and interest accrued	$ 0	$ 0
Temporary equity, shares outstanding (in Shares)	550,941	1,019,465
Shares of common stock (in Dollars per share)				$ 11.5
Exercisable, shares (in Shares)	0
General and administrative expense	$ 3,098,140	$ 1,287,276
Common Stock [Member]
Summary of Significant Accounting Policies [Line Items]
Shares of common stock (in Shares)				12,850,000
Common Class A [Member] | Public And Private Placement Warrants [Member]
Summary of Significant Accounting Policies [Line Items]
Common stock (in Shares)	12,850,000
Vaso Corporation and Subsidaries [Member]
Summary of Significant Accounting Policies [Line Items]
Common stock (in Shares)
Recognize revenue	$ 95,000,000
Performance obligations		$ 91,000,000
Deferred revenue	32,200,000	30,803,000	$ 24,965,000
Contract liability balance	9,200,000	9,100,000
Sales commission assets	2,561,000	2,732,000
Capitalized sales commissions	7,106,000	7,113,000
Deferred commission expense	3,285,000	3,249,000
Deferred long-term portion	3,821,000	3,864,000
Performance obligations	3,000	5,000
Unrecognized expense related to share-based compensation	114,000
Amortized cost	13,555,000
Short term investments	13,559,000
Unrecognized holding loss	4,000
Deposits	424,000	433,000
Insurance coverage	10,054,000
Foreign bank balances	467,000	1,234,000
Assets impaired
Software development costs	$ 253,000	0
Deferred tax asset	50%
Accrued payment of interest
Other comprehensive income (loss)	71,000	343,000
Vaso Corporation and Subsidaries [Member] | Intangible Assets [Member]
Summary of Significant Accounting Policies [Line Items]
Assets impaired
Vaso Corporation and Subsidaries [Member] | No Customer [Member]
Summary of Significant Accounting Policies [Line Items]
Revenues percentage	10%	10%
Vaso Corporation and Subsidaries [Member] | Selling, General and Administrative Expenses [Member]
Summary of Significant Accounting Policies [Line Items]
Share-based compensation expense	$ 48,000	$ 35,000
Vaso Corporation and Subsidaries [Member] | Restricted Stock [Member]
Summary of Significant Accounting Policies [Line Items]
Shares granted (in Shares)	225,000	1,050,000
Value of common stock (in Dollars per share)	$ 50,000	$ 115,000
Weighted average grant date fair value of shares granted (in Dollars per share)	$ 0.22	$ 0.11
Vaso Corporation and Subsidaries [Member] | Restricted Stock [Member] | Officer [Member]
Summary of Significant Accounting Policies [Line Items]
Total fair value of shares vested	$ 27,000	$ 23,000
Vaso Corporation and Subsidaries [Member] | Restricted Stock [Member] | Employees [Member]
Summary of Significant Accounting Policies [Line Items]
Total fair value of shares vested	24,000	4,000
Vaso Corporation and Subsidaries [Member] | Vaso Health Care [Member]
Summary of Significant Accounting Policies [Line Items]
Deferred revenue	$ 32,194,000	30,794,000
Vaso Corporation and Subsidaries [Member] | Minimum [Member] | Property, Plant and Equipment [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives	2 years
Vaso Corporation and Subsidaries [Member] | Minimum [Member] | Intangible Assets [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives	5 years
Vaso Corporation and Subsidaries [Member] | Maximum [Member] | Property, Plant and Equipment [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives	8 years
Vaso Corporation and Subsidaries [Member] | Maximum [Member] | Intangible Assets [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives	10 years
Short-Term Investments [Member] | Vaso Corporation and Subsidaries [Member]
Summary of Significant Accounting Policies [Line Items]
Amortized cost	$ 216,000
VHC IT [Member] | Vaso Corporation and Subsidaries [Member]
Summary of Significant Accounting Policies [Line Items]
Accrued expenses and other liabilities	419,000	481,000
General and administrative expense	75,000	79,000
GEHC [Member] | Vaso Corporation and Subsidaries [Member]
Summary of Significant Accounting Policies [Line Items]
Accrued expenses and other liabilities	$ 971,000	2,577,000
Percentage of revenue and accounts receivable	100%
Vaso Medical Business [Member] | Vaso Corporation and Subsidaries [Member]
Summary of Significant Accounting Policies [Line Items]
Deferred revenue	$ 6,000	$ 9,000
FDIC [Member] | Vaso Corporation and Subsidaries [Member]
Summary of Significant Accounting Policies [Line Items]
Insurance coverage	$ 250,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of the Common Stock Subject to Possible Redemption Reflected in the Balance Sheet Is Reconciled - Common Stock [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Temporary Equity [Line Items]
Gross proceeds			$ 100,000,000
Less:
Proceeds allocated to Public Warrants			(11,900,000)
Common Stock issuance costs			(5,322,219)
Plus: Remeasurement of carrying value to redemption value	$ 515,846	$ 998,892	18,722,219
Common Stock subject to possible redemption	6,049,745	10,489,562	$ 101,500,000
Less:
Redemption of Common Stock	$ (4,955,663)	(57,810,572)
Common Stock redemption payable		$ (34,198,758)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Net (Loss) Income Per Share - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Numerator:
Allocation of net (loss) income	$ (2,574,642)	$ 1,623,367
Denominator:
Weighted average shares outstanding	3,336,745	12,278,562
Basic and diluted net (loss) income per share	$ (0.77)	$ 0.13

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Net (Loss) Income Per Share (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Basic And Diluted Net (Loss) Income Per Share [Abstract]
Diluted net (loss) income per share	$ (0.77)	$ 0.13

Initial Public Offering (Detail

Initial Public Offering (Details) - $ / shares		12 Months Ended
	Oct. 19, 2021	Dec. 31, 2023
Initial Public Offering [Line Items]
Common stock price per share (in Dollars per share)	$ 11.5
IPO [Member]
Initial Public Offering [Line Items]
Number of sold units		10,000,000
Price per share (in Dollars per share)		$ 10
Number of shares in a unit	1	1
Number of warrants in a unit	1	1
Public warrant holder to purchase		1
Private Placement Warrants [Member]
Initial Public Offering [Line Items]
Common stock price per share (in Dollars per share)		$ 11.5

Private Placement Warrants (Det

Private Placement Warrants (Details) - USD ($)	Oct. 19, 2021	Dec. 31, 2023
Private Placement [Member]
Private Placement Warrants [Line Items]
Price per warrant	$ 0.75
IPO [Member]
Private Placement Warrants [Line Items]
Common stock shares		1
Private Placement Warrants [Member] | Private Placement [Member]
Private Placement Warrants [Line Items]
Sale of private placemets warrants	7,133,333
Gross proceeds	$ 5,350,000
Warrant [Member] | Private Placement [Member]
Private Placement Warrants [Line Items]
Common stock shares		1
Warrant [Member] | IPO [Member]
Private Placement Warrants [Line Items]
Price per share		$ 11.5

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 28, 2021	Dec. 31, 2023	Dec. 31, 2022	Jul. 18, 2023	Jan. 25, 2021
Related Party Transactions [Line Items]
Cash borrowing				$ 1,500,000
Outstanding loan amount		$ 582,000
Over-Allotment Option [Member]
Related Party Transactions [Line Items]
Number of shares subject to forfeiture (in Shares)		375,000
IPO [Member]
Related Party Transactions [Line Items]
Share issued, price per share (in Dollars per share)		$ 10
Vaso Corporation and Subsidaries [Member]
Related Party Transactions [Line Items]
Billed fees		$ 0	95,000
Common Stock [Member] | Restriction on Transfer of Founder Shares Event One [Member]
Related Party Transactions [Line Items]
Trading days		20 days
Trading days		30 days
Common Stock [Member] | Restriction on Transfer of Founder Shares Event One [Member] | Share Price Exceeds Twelve Point Fifty USD [Member]
Related Party Transactions [Line Items]
Exceeds per share (in Dollars per share)		$ 12.5
Working Capital Loans [Member]
Related Party Transactions [Line Items]
Working capital loans		$ 1,500,000
Warrant (in Dollars per share)		$ 0.75
Working capital loans outstanding
Sponsor [Member] | Founder Shares [Member]
Related Party Transactions [Line Items]
Aggregate purchase price	$ 25,000
Share issued, price per share (in Dollars per share)	$ 0.009
Consideration of common sock (in Shares)	2,156,250
Aggregate founder shares (in Shares)		2,875,000
Sponsor [Member] | Restriction on Transfer of Founder Shares Event One [Member] | Founder Shares [Member]
Related Party Transactions [Line Items]
Percentage of founder shares		50%
Sponsor [Member] | Restriction on Transfer of Founder Shares Event Two [Member] | Founder Shares [Member]
Related Party Transactions [Line Items]
Percentage of founder shares		50%
Sponsor [Member] | IPO [Member]
Related Party Transactions [Line Items]
Issued and outstanding percentage		20%
Sponsor [Member] | Promissory Note [Member]
Related Party Transactions [Line Items]
Aggregate principal amount					$ 300,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)		12 Months Ended
	May 10, 2019	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies [Line Items]
Deferred underwriting commissions closing		$ 3,500,000	$ 3,500,000
IPO [Member]
Commitments and Contingencies [Line Items]
Aggregate closing amount		2,000,000
Deferred underwriting commissions closing		3,500,000
Underwriting Agreement [Member]
Commitments and Contingencies [Line Items]
Deferred underwriting commissions closing		$ 3,500,000
Underwriting Agreement [Member] | Over-Allotment Option [Member]
Commitments and Contingencies [Line Items]
Underwriters option day		45 days
Initial public offering to purchase (in Shares)		1,500,000
Underwriting Agreement [Member] | IPO [Member]
Commitments and Contingencies [Line Items]
Underwriters option day		45 days
Cash underwriting discount (in Dollars per share)		$ 0.2
Deferred underwriting commissions (in Dollars per share)		$ 0.35
Vaso Corporation and Subsidaries [Member]
Commitments and Contingencies [Line Items]
Employment agreement for annual compensation	$ 500,000	$ 350,000
Vaso Corporation and Subsidaries [Member] | Billed Revenues [Member]
Commitments and Contingencies [Line Items]
Monthly recurring charges		$ 337,000	$ 339,000

Stockholders_ Deficit (Details)

Stockholders’ Deficit (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	May 31, 2023	Dec. 31, 2022	Oct. 19, 2021	Jun. 15, 2016	Oct. 30, 2013
Stockholders’ Deficit [Line Items]
Common stock shares authorized	100,000,000		100,000,000
Common stock shares issued	2,500,000		2,500,000
Common stock shares outstanding	2,500,000		2,500,000
Subject to possible redemption	550,941		1,019,465
Preferred stock shares authorized	1,000,000		1,000,000
Preferred stock par value (in Dollars per share)	$ 0.0001		$ 0.0001
Preferred stock shares issued
Preferred stock shares outstanding
Class Of Warrant Or Right Number Of Days After The Completion Of Business Combination From Which Warrants Or Rights Becomes Exercisable	30 days
Number of business days	15 days
Common Stock [Member]
Stockholders’ Deficit [Line Items]
Number Of Trading Days Determining Share Price	20 days
Trading days	30 days
Warrants outstanding				12,850,000
Vaso Corporation and Subsidaries [Member]
Stockholders’ Deficit [Line Items]
Common stock shares authorized	250,000,000		250,000,000
Common stock shares issued	185,627,383	15,000,000	185,435,965		7,500,000	7,500,000
Common stock shares outstanding	175,319,296		175,127,878
Preferred stock shares authorized	1,000,000		1,000,000
Preferred stock par value (in Dollars per share)	$ 0.01		$ 0.01
Preferred stock shares issued
Preferred stock shares outstanding
Withholding tax	10%
Reserves reaches	50%
Statutory reserves (in Dollars)	$ 35,000		$ 35,000
Share Price Equals or Exceeds Sixteen Point Fifty USD [Member] | Common Stock [Member]
Stockholders’ Deficit [Line Items]
Exceeds per share (in Dollars per share)	$ 16.5
Public Warrants [Member]
Stockholders’ Deficit [Line Items]
Initial public offering	1 year
Expire year	5 years
Price per share (in Dollars per share)	$ 0.01
Notice of redemption period	30 days
Warrants outstanding	10,000,000		10,000,000

Warrant Liabilities (Details)

Warrant Liabilities (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Oct. 19, 2021
Warrant Liabilities [Line Items]
Exercise price			$ 11.5
Percentage of exercise price warrants	115%
Common Stock [Member]
Warrant Liabilities [Line Items]
Equity proceeds	60%
Trading day period	20 days
Exercise price	$ 9.5
Share Price Less Than Nine Point Fifty USD [Member] | Common Stock [Member]
Warrant Liabilities [Line Items]
Common stock of per share	$ 9.5
Private Warrants [Member]
Warrant Liabilities [Line Items]
Private warrants outstanding	7,133,333	7,133,333

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of Liabilities that are Measured at Fair Value on a Recurring Basis - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Quoted Prices in Active Markets (Level 1) [Member]
Assets:
Cash and marketable securities held in Trust Account	$ 6,049,745	$ 44,688,320
Warrant Liability-Private Placement Warrants
Significant Other Observable Inputs (Level 2) [Member]
Assets:
Cash and marketable securities held in Trust Account
Warrant Liability-Private Placement Warrants
Significant Other Unobservable Inputs (Level 3) [Member]
Assets:
Cash and marketable securities held in Trust Account
Warrant Liability-Private Placement Warrants	$ 107,713	$ 356,666

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - Schedule of Level 3 Fair Value Measurements	Dec. 31, 2023	Dec. 31, 2022
Stock Price [Member]
Schedule of Level 3 Fair Value Measurements [Line Items]
Warrant measurement input	10.89	10.22
Exercise Price [Member]
Schedule of Level 3 Fair Value Measurements [Line Items]
Warrant measurement input	11.5	11.5
Term [Member]
Schedule of Level 3 Fair Value Measurements [Line Items]
Warrant measurement input	0.96	2.91
Volatility [Member]
Schedule of Level 3 Fair Value Measurements [Line Items]
Warrant measurement input	1.15	0.2
Risk Free Rate [Member]
Schedule of Level 3 Fair Value Measurements [Line Items]
Warrant measurement input	4.77	4.24
Dividend Yield [Member]
Schedule of Level 3 Fair Value Measurements [Line Items]
Warrant measurement input	0	0

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) - Schedule of Changes in the Fair Value of Level 3 Warrant Labilities - Private Placement Warrants [Member] - USD ($)	2 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2023	Dec. 31, 2022
Fair Value Measurements (Details) - Schedule of Changes in the Fair Value of Level 3 Warrant Labilities [Line Items]
Fair value as of October 19, 2021 (IPO)	$ 2,354,000	$ 107,713	$ 356,666
Change in fair value	(7,632,666)	(248,953)	(1,997,334)
Fair value , ending	2,354,000	107,713	356,666
Fair value , beginning		$ 356,666	$ 2,354,000
IPO [Member]
Fair Value Measurements (Details) - Schedule of Changes in the Fair Value of Level 3 Warrant Labilities [Line Items]
Fair value as of October 19, 2021 (IPO)
Fair value , beginning	$ 9,986,666

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Taxes (Details) [Line Items]
Net operating loss carryforwards	$ 0	$ 0
Change in valuation allowance	$ 688,629	$ 308,347
Tax provision statutory rate	21%	21%
Income tax expense	$ 72,980	$ 216,203
State income tax	50,000,000	36,000,000
Reduction in deferred tax assets	51,000,000
Foreign tax benefit	(1,000,000)	9,000,000
Deferred tax assets	688,629	308,347
Decrease in deferred tax assets	459,000,000
Valuation allowance	3,663,000,000
Reflecting decrease valuation allowance	$ 880,000,000
Net operating loss carryforwards expiration date	expiring at various dates from 2023 through 2037
Maximum [Member]
Income Taxes (Details) [Line Items]
Net operating loss carryforwards	$ 18,000,000
Minimum [Member]
Income Taxes (Details) [Line Items]
Net operating loss carryforwards	7,000,000
Achari Ventures Holdings Corp [Member]
Income Taxes (Details) [Line Items]
Change in valuation allowance	688,629	308,347
Income tax expense	(72,980)
Deferred Tax Assets [Member]
Income Taxes (Details) [Line Items]
Income tax expense	100,000,000	$ (4,743,000,000)
Deferred tax assets	$ 11,547,000,000

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of Income Tax Provision - Achari Ventures Holdings Corp [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Federal
Current	$ 72,980
Deferred	(688,629)
State and local
Current
Deferred
Change in valuation allowance	688,629
Income tax provision	$ 72,980
Current		$ 216,203
Deferred		(246,333)
Current
Deferred
Change in valuation allowance		246,333
Income tax provision		$ 216,203

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of Deferred Tax Assets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Deferred Tax Assets and Liabilities [Abstract]
Start-up costs	$ 688,629	$ 308,347
Net operating loss carryforward
Total deferred tax asset	688,629	308,347
Valuation allowance	(688,629)	(308,347)
Deferred tax asset net of allowance

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of Effective Tax Rate	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Statutory federal income tax rate	21%	21%
State taxes, net of federal tax benefit	0%	0%
Change in fair value of warrants	9.95%	(22.80%)
Warrant issuance costs	0%	0%
Valuation allowance	(27.53%)	13.29%
Income tax provision expense	(3.42%)	11.49%

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Mar. 19, 2024	Mar. 13, 2024
Subsequent Events [Line Items]
Company’s trust account	$ 6,145,817	$ 22,037.64
Deposit	$ 22,037.64

Revisions (Details)

Revisions (Details) - USD ($)		12 Months Ended
	Jan. 01, 2022	Dec. 31, 2022	Dec. 31, 2023
Revisions [Line Items]
Accumulated deficit	$ 229,000,000	$ (4,251,812)	$ (7,733,844)
Commission revenue	$ 287,000,000
Commission expense		$ 58,000,000

Revisions (Details) - Schedule

Revisions (Details) - Schedule of Consolidated Financial Statements - Vaso Corporation and Subsidaries [Member] $ in Thousands	Dec. 31, 2022 USD ($)
As Reported [Member]
Schedule of Consolidated Financial Statements [Line Items]
Accounts and other receivables	$ 15,524
Accrued commissions	3,720
Accumulated deficit	(39,029)
Adjustment [Member]
Schedule of Consolidated Financial Statements [Line Items]
Accounts and other receivables	(1,010)
Accrued commissions	(202)
Accumulated deficit	(808)
As Revised [Member]
Schedule of Consolidated Financial Statements [Line Items]
Accounts and other receivables	14,514
Accrued commissions	3,518
Accumulated deficit	$ (39,837)

Revisions (Details) - Schedul_2

Revisions (Details) - Schedule of Consolidated Statement of Operations and Comprehensive Income - Vaso Corporation and Subsidaries [Member] $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares
As Reported [Member]
Schedule of Consolidated Statement of Operations and Comprehensive Income [Line Items]
Operating income	$ 7,033
Net income	11,873
Comprehensive income	$ 11,530
– basic (in Dollars per share) | $ / shares	$ 0.07
– diluted (in Dollars per share) | $ / shares	$ 0.07
As Reported [Member] | Professional Sales Services [Member]
Schedule of Consolidated Statement of Operations and Comprehensive Income [Line Items]
Professional sales services	$ 37,344
Cost of professional sales services	7,056
As Reported [Member] | Professional Sales Services Segment [Member]
Schedule of Consolidated Statement of Operations and Comprehensive Income [Line Items]
Gross Profit – professional sales services segment	30,288
Adjustment [Member]
Schedule of Consolidated Statement of Operations and Comprehensive Income [Line Items]
Operating income	(579)
Net income	(579)
Comprehensive income	$ (579)
– basic (in Dollars per share) | $ / shares	$ 0
– diluted (in Dollars per share) | $ / shares	$ 0
Adjustment [Member] | Professional Sales Services [Member]
Schedule of Consolidated Statement of Operations and Comprehensive Income [Line Items]
Professional sales services	$ (723)
Cost of professional sales services	(144)
Adjustment [Member] | Professional Sales Services Segment [Member]
Schedule of Consolidated Statement of Operations and Comprehensive Income [Line Items]
Gross Profit – professional sales services segment	(579)
As Revised [Member]
Schedule of Consolidated Statement of Operations and Comprehensive Income [Line Items]
Operating income	6,454
Net income	11,294
Comprehensive income	$ 10,951
– basic (in Dollars per share) | $ / shares	$ 0.07
– diluted (in Dollars per share) | $ / shares	$ 0.06
As Revised [Member] | Professional Sales Services [Member]
Schedule of Consolidated Statement of Operations and Comprehensive Income [Line Items]
Professional sales services	$ 36,621
Cost of professional sales services	6,912
As Revised [Member] | Professional Sales Services Segment [Member]
Schedule of Consolidated Statement of Operations and Comprehensive Income [Line Items]
Gross Profit – professional sales services segment	$ 29,709

Revisions (Details) - Schedul_3

Revisions (Details) - Schedule of Consolidated Statement of Changes in Stockholders’ Equity - Vaso Corporation and Subsidaries [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
As Reported [Member]
Schedule of Consolidated Statement of Changes in Stockholders’ Equity [Line Items]
Balance	$ 11,310
Net income	11,873
Balance	22,875
As Reported [Member] | Accumulated Deficit [Member]
Schedule of Consolidated Statement of Changes in Stockholders’ Equity [Line Items]
Balance	(50,902)
Net income	11,873
Balance	(39,029)
Adjustment [Member]
Schedule of Consolidated Statement of Changes in Stockholders’ Equity [Line Items]
Balance	(229)
Net income	(579)
Balance	(808)
Adjustment [Member] | Accumulated Deficit [Member]
Schedule of Consolidated Statement of Changes in Stockholders’ Equity [Line Items]
Balance	(229)
Net income	(579)
Balance	(808)
As Revised [Member]
Schedule of Consolidated Statement of Changes in Stockholders’ Equity [Line Items]
Balance	11,081
Net income	11,294
Balance	22,067
As Revised [Member] | Accumulated Deficit [Member]
Schedule of Consolidated Statement of Changes in Stockholders’ Equity [Line Items]
Balance	(51,131)
Net income	11,294
Balance	$ (39,837)

Revisions (Details) - Schedul_4

Revisions (Details) - Schedule of Consolidated Statement of Cash Flows - Vaso Corporation and Subsidaries [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
As Reported [Member]
Schedule of Consolidated Statement of Cash Flows [Line Items]
Net income	$ 11,873
Accounts and other receivables	(243)
Accrued commissions	1,094
Adjustment [Member]
Schedule of Consolidated Statement of Cash Flows [Line Items]
Net income	(579)
Accounts and other receivables	723
Accrued commissions	(144)
As Revised [Member]
Schedule of Consolidated Statement of Cash Flows [Line Items]
Net income	11,294
Accounts and other receivables	480
Accrued commissions	$ 950

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details) - Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	$ 81,024	$ 79,294
IT Segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	40,371	40,100
Professional sales service segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	37,820	36,621
Equipment segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	2,833	2,573
Network Services
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	35,673	35,833
Network Services | IT Segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	35,673	35,833
Network Services | Professional sales service segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition
Network Services | Equipment segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition
Software Sales and Support
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	4,698	4,267
Software Sales and Support | IT Segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	4,698	4,267
Software Sales and Support | Professional sales service segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition
Software Sales and Support | Equipment segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition
Commissions
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	37,820	36,621
Commissions | IT Segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition
Commissions | Professional sales service segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	37,820	36,621
Commissions | Equipment segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition
Medical Equipment Sales
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	2,708	2,450
Medical Equipment Sales | IT Segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition
Medical Equipment Sales | Professional sales service segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition
Medical Equipment Sales | Equipment segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	2,708	2,450
Medical Equipment Service
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	125	123
Medical Equipment Service | IT Segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition
Medical Equipment Service | Professional sales service segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition
Medical Equipment Service | Equipment segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	125	123
Revenue Recognized Over Time [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	37,823	37,414
Revenue Recognized Over Time [Member] | IT Segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	37,223	37,089
Revenue Recognized Over Time [Member] | Professional sales service segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition
Revenue Recognized Over Time [Member] | Equipment segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	600	325
Revenue Recognized at a Point in Time [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	43,201	41,880
Revenue Recognized at a Point in Time [Member] | IT Segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	3,148	3,011
Revenue Recognized at a Point in Time [Member] | Professional sales service segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	37,820	36,621
Revenue Recognized at a Point in Time [Member] | Equipment segment [Member]
Schedule of Revenues Disaggregated by Our Business Operations and Timing of Revenue Recognition [Line Items]
Revenue recognition	$ 2,233	$ 2,248

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Details) - Schedule of Aggregate Amount of Transaction Price Allocated to Performance Obligations - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	Dec. 31, 2026	Dec. 31, 2025	Dec. 31, 2024
Revenue Recognition Over Next Twelve Months [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Unfulfilled performance obligations			$ 44,667
Revenue Recognition Over Two Years [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Unfulfilled performance obligations		$ 19,861
Revenue Recognition Over Three Years [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Unfulfilled performance obligations	$ 6,240
Revenue Recognition More Than Four Years [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Unfulfilled performance obligations	$ 23,918

Summary of Significant Accoun_9

Summary of Significant Accounting Policies (Details) - Schedule of Contract Receivable and Contract Liability Balances - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies (Details) - Schedule of Contract Receivable and Contract Liability Balances [Line Items]
Contract receivables	$ 15,306	$ 15,474
Contract receivables	13,398	15,306
Increase (decrease), contract receivables	(1,909)	(168)
Contract liabilities	33,861	26,890
Contract liabilities	33,589	33,861
Increase (decrease), contract liabilities	$ (272)	$ 6,971

Summary of Significant Accou_10

Summary of Significant Accounting Policies (Details) - Schedule of Company’s Assets Measured at Fair Value - Vaso Corporation and Subsidaries [Member] - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Company’s Assets Measured at Fair Value [Line Items]
Cash equivalents invested in money market funds and treasury bills	$ 10,522,000	$ 7,934,000
Bank deposits (included in short term investments)	424,000	433,000
Fair Value of Assets	10,946,000	8,367,000
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Schedule of Company’s Assets Measured at Fair Value [Line Items]
Cash equivalents invested in money market funds and treasury bills	10,522,000	7,934,000
Bank deposits (included in short term investments)	424,000	433,000
Fair Value of Assets	10,946,000	8,367,000
Significant Other Observable Inputs (Level 2) [Member]
Schedule of Company’s Assets Measured at Fair Value [Line Items]
Cash equivalents invested in money market funds and treasury bills
Fair Value of Assets
Significant Unobservable Inputs (Level 3) [Member]
Schedule of Company’s Assets Measured at Fair Value [Line Items]
Cash equivalents invested in money market funds and treasury bills
Fair Value of Assets

Summary of Significant Accou_11

Summary of Significant Accounting Policies (Details) - Schedule of Company’s Allowance for Doubtful Accounts and Commission Adjustments - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies (Details) - Schedule of Company’s Allowance for Doubtful Accounts and Commission Adjustments [Line Items]
Beginning Balance	$ 6,947	$ 5,804
Provision for losses on accounts receivable	66	63
Direct write-offs, net of recoveries	(60)	(159)
Commission adjustments	2,755	1,239
Ending Balance	$ 9,708	$ 6,947

Summary of Significant Accou_12

Summary of Significant Accounting Policies (Details) - Schedule of Basic to Diluted Shares Used in the Earnings Per Share - Vaso Corporation and Subsidaries [Member] - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Basic weighted average shares outstanding	174,441	173,065
Dilutive effect of unvested restricted shares	1,100	1,591
Diluted weighted average shares outstanding	175,541	174,656

Segment Reporting (Details)

Segment Reporting (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | GEHC [Member]
Segment Reporting [Line Items]
Revenue percentage		46%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vaso Corporation and Subsidaries [Member] | GEHC [Member]
Segment Reporting [Line Items]
Revenue percentage	47%
Accounts Receivable [Member] | Vaso Corporation and Subsidaries [Member]
Segment Reporting [Line Items]
Accounts and other receivables (in Dollars)		$ 11.8
Accounts Receivable [Member] | Vaso Corporation and Subsidaries [Member] | GEHC [Member]
Segment Reporting [Line Items]
Accounts and other receivables (in Dollars)	$ 9.3
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Vaso Corporation and Subsidaries [Member] | GEHC [Member]
Segment Reporting [Line Items]
Revenue percentage	75%	81%

Segment Reporting (Details) - S

Segment Reporting (Details) - Schedule of Financial Information - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues from external customers
Total revenues	$ 81,024	$ 79,294
Gross Profit
Total gross profit	50,593	47,902
Operating income (loss)
Total operating income	4,195	6,454
Depreciation and amortization
Total depreciation and amortization	999	1,923
Capital expenditures
Total cash capital expenditures	731	566
Identifiable Assets
Total assets	75,757	71,645
IT [Member]
Revenues from external customers
Total revenues	40,371	40,100
Operating income (loss)
Total operating income	(466)	(1,620)
Capital expenditures
Total cash capital expenditures	357	406
Identifiable Assets
Total assets	22,425	22,201
Professional sales service [Member]
Capital expenditures
Total cash capital expenditures	87	125
Identifiable Assets
Total assets	18,955	20,674
Corporate [Member]
Identifiable Assets
Total assets	27,263	21,813
IT [Member]
Revenues from external customers
Total revenues	40,371	40,100
Gross Profit
Total gross profit	17,659	16,229
Depreciation and amortization
Total depreciation and amortization	869	1,692
Professional sales service [Member]
Revenues from external customers
Total revenues	37,820	36,621
Gross Profit
Total gross profit	30,799	29,709
Operating income (loss)
Total operating income	7,195	9,520
Depreciation and amortization
Total depreciation and amortization	84	33
Corporate [Member]
Operating income (loss)
Total operating income	(2,083)	(1,266)
Depreciation and amortization
Total depreciation and amortization
Capital expenditures
Total cash capital expenditures		1
Equipment [Member]
Revenues from external customers
Total revenues	2,833	2,573
Gross Profit
Total gross profit	2,135	1,964
Operating income (loss)
Total operating income	(451)	(180)
Depreciation and amortization
Total depreciation and amortization	46	198
Identifiable Assets
Total assets	7,114	6,957
Equipment [Member]
Capital expenditures
Total cash capital expenditures	$ 287	$ 34

Segment Reporting (Details) -_2

Segment Reporting (Details) - Schedule of Geographic Areas - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 81,024	$ 79,294
Domestic United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	78,843	77,062
Non-domestic foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 2,181	$ 2,232

Accounts and Other Receivable_2

Accounts and Other Receivables (Details) - Schedule of Accounts and Other Receivables - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Trade receivables	$ 22,085	$ 21,461
Allowance for credit losses and commission adjustments	(9,708)	(6,947)
Accounts and other receivables, net	$ 12,377	$ 14,514

Inventories (Details)

Inventories (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Inventories [Line Items]
Reserve for slow moving inventories	$ 164,000	$ 163,000

Inventories (Details) - Schedul

Inventories (Details) - Schedule of Inventories, Net of Reserves - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Inventory [Line Items]
Raw materials	$ 832	$ 751
Work in process	11	6
Finished goods	627	716
Total	$ 1,470	$ 1,473

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Property and Equipment [Line Items]
Finance leases accumulated amortization	$ 951,000	$ 858,000
Depreciation expense	$ 635,000	$ 1,372,000

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and Equipment - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	$ 11,532	$ 11,127
Less: accumulated depreciation and amortization	(10,358)	(9,787)
Property and equipment, net	1,174	1,340
Office, laboratory and other equipment [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	2,084	1,928
Equipment furnished for customer or clinical uses [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	8,233	7,981
Right of use assets - finance leases [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	1,116	1,119
Furniture and fixtures [Member]
Schedule of Property and Equipment [Line Items]
Property and equipment, gross	$ 99	$ 99

Goodwill and Other Intangible_2

Goodwill and Other Intangibles (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Other Intangibles [Abstract]
Amortization Expense	$ 361,000	$ 551,000
Maximum [Member]
Goodwill and Other Intangibles [Abstract]
Straight-line method years	10 years
Minimum [Member]
Goodwill and Other Intangibles [Abstract]
Straight-line method years	8 years
NetWolves Reporting Unit [Member]
Goodwill and Other Intangibles [Abstract]
Goodwill	$ 14,375,000
FGE Reporting Unit [Member]
Goodwill and Other Intangibles [Abstract]
Goodwill	$ 1,213,000

Goodwill and Other Intangible_3

Goodwill and Other Intangibles (Details) - Schedule of Change in Carrying Amount of Goodwill - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Change in Goodwill [Abstract]
Beginning of period	$ 15,614	$ 15,722
Foreign currency translation adjustment	(26)	(108)
End of period	$ 15,588	$ 15,614

Goodwill and Other Intangible_4

Goodwill and Other Intangibles (Details) - Schedule of Other Intangible Assets - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Other Intangible Assets [Line Items]
Intangible assets, net	$ 1,406	$ 1,511
Customer-related [Member]
Schedule of Other Intangible Assets [Line Items]
Costs	5,831	5,831
Accumulated amortization	(4,790)	(4,557)
Intangible assets, net	1,041	1,274
Patents and Technology [Member]
Schedule of Other Intangible Assets [Line Items]
Costs	1,894	1,894
Accumulated amortization	(1,894)	(1,894)
Intangible assets, net
Software [Member]
Schedule of Other Intangible Assets [Line Items]
Costs	2,618	2,362
Accumulated amortization	(2,253)	(2,125)
Intangible assets, net	$ 365	$ 237

Goodwill and Other Intangible_5

Goodwill and Other Intangibles (Details) - Schedule of Amortization of Intangibles - Vaso Corporation and Subsidaries [Member] $ in Thousands	Dec. 31, 2023 USD ($)
Schedule of Amortization of Intangibles [Abstract]
2024	$ 325
2025	254
2026	199
2027	169
2028	131
Intangibles net	$ 1,078

Other Assets (Details) - Schedu

Other Assets (Details) - Schedule of Other Assets - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Other Assets (Details) - Schedule of Other Assets [Line Items]
Deferred commission expense – noncurrent	$ 3,821	$ 3,864
Trade receivables – noncurrent	1,021	792
Other, net of allowance for loss on loan receivable of $412 at December 31, 2023 and 2022	60	70
Total other assets net	$ 4,902	$ 4,726

Other Assets (Details) - Sche_2

Other Assets (Details) - Schedule of Other Assets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Vaso Corporation and Subsidaries [Member]
Other Assets (Details) - Schedule of Other Assets (Parentheticals) [Line Items]
Allowance for loss on loan receivable	$ 412	$ 412

Deferred Revenue (Details) - Sc

Deferred Revenue (Details) - Schedule of Deferred Revenues - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Deferred Revenues [Line Items]
Deferred revenue at beginning of period	$ 30,803	$ 24,965
Recognized as revenue:
Deferred revenue at end of period	32,200	30,803
Less: current portion	15,883	15,139
Long-term deferred revenue at end of period	16,317	15,664
Deferred extended service contracts [Member]
Net additions:
Net additions	2	3
Recognized as revenue:
Recognized as revenue	(4)	(4)
Deferred commission revenues [Member]
Net additions:
Net additions	15,064	19,666
Recognized as revenue:
Recognized as revenue	$ (13,665)	$ (13,827)

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - Schedule of Accrued Expenses and Other Liabilities - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Accrued Expenses and Other Liabilities (Details) - Schedule of Accrued Expenses and Other Liabilities [Line Items]
Accrued compensation	$ 2,482	$ 2,652
Accrued expenses – other	2,142	2,012
Order reduction liability	971	2,577
Other liabilities	1,770	1,650
Accrued Expenses and Other Liabilities	$ 7,365	$ 8,891

Notes Payable and Revolving C_3

Notes Payable and Revolving Credit Agreement (Details) - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Millions	1 Months Ended
	Dec. 30, 2022	Dec. 31, 2023
Notes Payable and Revolving Credit Agreement [Abstract]
Bears interest		1.90%
Amount of revolving credit agreement	$ 3

Notes Payable and Revolving C_4

Notes Payable and Revolving Credit Agreement (Details) - Schedule of Notes Payable - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Short-Term Debt [Line Items]
Notes payable	$ 15	$ 24
Less: current portion	(9)	(9)
Total notes payable	$ 6	$ 15

Leases (Details)

Leases (Details)	12 Months Ended
	Dec. 31, 2023
Leases [Line Items]
Assets and liabilities leases term	12 months
Minimum [Member]
Leases [Line Items]
Finance leases term	3 years
Operating lease terms	2 years
Maximum [Member]
Leases [Line Items]
Finance leases term	5 years
Operating lease terms	7 years

Leases (Details) - Schedule of

Leases (Details) - Schedule of Finance and Operating Lease Liabilities - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Lease liabilities – current
Finance leases	$ 72	$ 122
Operating leases	928	745
Total lease liabilities - current	1,000	867
Lease liabilities – net of current portion
Finance leases	25	96
Operating leases	1,020	823
Total lease liabilities - noncurrent	$ 1,045	$ 919

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Undiscounted Cash Flows to Finance and Operating Lease Liabilities - Vaso Corporation and Subsidaries [Member] $ in Thousands	Dec. 31, 2023 USD ($)
Leases (Details) - Schedule of Undiscounted Cash Flows to Finance and Operating Lease Liabilities [Line Items]
Finance leases 2024	$ 83
Operating leases 2024	932
Total 2024	1,015
Finance leases 2025	25
Operating leases 2025	697
Total 2025	722
Finance leases 2026
Operating leases 2026	406
Total 2026	406
Finance leases 2027
Operating leases 2027	124
Total 2027	124
Finance leases Undiscounted lease payments	108
Operating leases Undiscounted lease payments	2,159
Total Undiscounted lease payments	2,267
Finance leases Amount representing interest	(11)
Operating leases Amount representing interest	(211)
Total Amount representing interest	(222)
Finance leases Discounted lease liabilities	97
Operating leases Discounted lease liabilities	1,948
Total Discounted lease liabilities	$ 2,045

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of Additional Disclosures of Lease Data - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Finance lease costs:
Amortization of right-of-use assets	$ 107	$ 154
Interest on lease liabilities	23	44
Total finance lease costs	130	198
Operating lease costs	1,011	878
Short-term lease costs	52	52
Total lease cost	1,193	1,128
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from finance leases	144	44
Operating cash flows from operating leases	1,011	878
Financing cash flows from finance leases	119	222
Total cash paid for amounts included in the measurement of lease liabilities	$ 1,274	$ 1,144
Weighted-average remaining lease term - finance leases (months)	16 months	23 months
Weighted-average remaining lease term - operating leases (months)	31 months	30 months
Weighted-average discount rate - finance leases	16.40%	14.20%
Weighted-average discount rate - operating leases	8.40%	9.10%

Equity in the Eecp Business (De

Equity in the Eecp Business (Details) - USD ($)		12 Months Ended
	May 20, 2020	Dec. 31, 2023	Dec. 31, 2022
Equity in the EECP Business [Line Items]
Sale of stock percentage	51%
Company closed on the sale	$ 1,150,000
E E C P Global Corporation [Member]
Equity in the EECP Business [Line Items]
Loss from investment		$ (206,000)	$ (154,000)
Related Party [Member]
Equity in the EECP Business [Line Items]
Receivables due from related parties		$ 901,000	$ 403,000

Option and Stock Issuance Pla_3

Option and Stock Issuance Plans (Details) - Vaso Corporation and Subsidaries [Member] - shares	12 Months Ended
	Dec. 31, 2023	May 31, 2023	Dec. 31, 2022	Jun. 15, 2016	Oct. 30, 2013
Option and Stock Issuance Plans [Line Items]
Common stock issued	185,627,383	15,000,000	185,435,965	7,500,000	7,500,000
Shares forfeited	759,120
Withheld for withholding taxes	3,540
Common stock issued granted	225,000
Remaining authorized shares of common stock	54,317,575
2016 Plan [Member]
Option and Stock Issuance Plans [Line Items]
Withheld for withholding taxes	21,709

Option and Stock Issuance Pla_4

Option and Stock Issuance Plans (Details) - Schedule of Non Vested Restricted Share - Non-vested restricted shares [Member] - Vaso Corporation and Subsidaries [Member] - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Non Vested Restricted Share [Line Items]
Shares Available for Future Issuance, Begining Balance	9,955,580	10,915,580
Unvested shares, Begining Balance	2,650,000	2,990,000
Weighted Average Grant Date Fair Value, Begining Balance (in Dollars per share)	$ 0.06	$ 0.02
Weighted Average Grant Date Fair Value, Authorized (in Dollars per share)
Shares Available for Future Issuance, Authorized
Unvested shares, Authorized
Shares Available for Future Issuance, Granted	(225,000)	(1,050,000)
Unvested shares, Granted	225,000	1,050,000
Weighted Average Grant Date Fair Value, Granted (in Dollars per share)	$ 0.22	$ 0.11
Unvested shares, Vested	(1,491,418)	(1,300,000)
Weighted Average Grant Date Fair Value, Vested (in Dollars per share)	$ 0.03	$ 0.02
Shares Available for Future Issuance, Vested
Weighted Average Grant Date Fair Value, Forfeited (in Dollars per share)	$ 0.11	$ 0.05
Shares Available for Future Issuance, Forfeited	25,249	90,000
Unvested shares, Forfeited	(25,249)	(90,000)
Weighted Average Grant Date Fair Value, Expired (in Dollars per share)
Shares Available for Future Issuance, Expired	(759,120)
Unvested shares, Expired
Shares Available for Future Issuance, Ending Balance	8,996,709	9,955,580
Unvested shares, Ending Balance	1,358,333	2,650,000
Weighted Average Grant Date Fair Value, Ending Balance (in Dollars per share)	$ 0.11	$ 0.06

Income Taxes (Details) - Sche_4

Income Taxes (Details) - Schedule of Geographical Breakdown of Income Before Provision for Income Taxes - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Geographical Breakdown of Income Before Provision for Income Taxes [Line Items]
Domestic	$ 5,085	$ 6,244
Foreign	(180)	307
Income before provision for income taxes	$ 4,905	$ 6,551

Income Taxes (Details) - Sche_5

Income Taxes (Details) - Schedule of Provision for Income Taxes - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Provision for Income Taxes [Line Items]
Federal
State	50	36
Foreign	(1)	9
Total current provision (benefit)	49	45
Federal	40	(3,724)
State	11	(1,064)
Foreign
Total deferred provision (benefit)	51	(4,788)
Total income tax provision (benefit)	$ 100	$ (4,743)
Effective income tax rate	2.04%	(72.40%)

Income Taxes (Details) - Sche_6

Income Taxes (Details) - Schedule of Reconciliation of the Effective Income Tax Rate - Vaso Corporation and Subsidaries [Member]	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Reconciliation of the Effective Income Tax Rate [Line Items]
Federal statutory rate	21%	21%
State income taxes	6.19%	6.11%
Change in valuation allowance relating to operations	(17.96%)	(92.63%)
Foreign tax rate differential	(2.71%)	(0.81%)
R&D credit	1.87%	0.58%
Nondeductible expenses	0.71%	0.22%
Other	(7.06%)	(6.87%)
Income tax provision expense	2.04%	(72.40%)

Income Taxes (Details) - Sche_7

Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of deferred tax assets and liabilities [Line Items]
Net operating loss carryforwards	$ 6,796	$ 8,367
Amortization	590	328
Stock-based compensation	4	7
Allowance for doubtful accounts	100	99
Reserve for slow moving inventory	46	46
Tax credits	324	416
Expense accruals	855	908
Capitalized R&D	13
Deferred revenue	2,819	1,835
Total deferred tax asset	11,547	12,006
Valuation allowance	(3,663)	(4,543)	$ (10,769)
Net deferred tax assets	7,884	7,463
Deferred commissions	(701)	(464)
Goodwill	(2,221)	(1,962)
Depreciation	(7)	(30)
Total deferred tax liabilities	(2,929)	(2,456)
Total deferred tax assets (liabilities)	4,955	5,007
Non-current deferred tax assets	4,955	5,007
Non-current deferred tax liabilities

Income Taxes (Details) - Sche_8

Income Taxes (Details) - Schedule of the Valuation Allowance - Vaso Corporation and Subsidaries [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of the Valuation Allowance [Line Items]
Valuation allowance, beginning of period	$ 4,543	$ 10,769
Partial release of allowance		(4,840)
Change in valuation allowance	(880)	(1,386)
Valuation allowance, end of period	$ 3,663	$ 4,543

401(k) Plans (Details)

401(k) Plans (Details) - Vaso Corporation and Subsidaries [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
401(k) Plans (Details) [Line Items]
Voluntary contributions rate	80%
Percentage of employee contributions	$ 234,000	$ 112,000